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ABSTRACT 
 
DEVELOPING A PRECLINICAL MODEL OF HUMAN SUNITINIB CARDIOTOXICITY TO 
ASSESS THE ROLE OF MECHANICAL LOADING USING ENGINEERED CARDIAC 
MICROTISSUES 
Rachel Elizabeth Truitt 
Kenneth B. Margulies, MD 
Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to treat many solid 
tumors, has led to important survival gains. However, this agent carries a significant risk 
of cardiotoxicity, with left ventricular dysfunction reported in up to 9.7% of treated 
individuals, and hypertension in 11-43%. There are a number of proposed mechanisms 
for sunitinib cardiotoxicity, however the relative contribution of each remains poorly 
understood. In particular, the relationship between increased left ventricular afterload 
toward inducing cardiac dysfunction remains unknown. Shortcomings of conventional 
cell culture and rodent models have hampered the identification of pivotal mechanisms of 
cardiotoxicity such as increased afterload. We instead chose to utilize a recently 
developed 3D in vitro microtissue model, where rat myocytes self-assemble to form 
microtissues.  
Our model of human sunitinib cardiotoxicity recapitulated characteristics 
observed by other research groups, specifically, cardiomyocyte death, decreases in force 
generation and spontaneous beating, and demonstrated the dependence of these 
characteristics on sunitinib dose and treatment duration. Additionally, we observed 
decreases in mitochondrial membrane potential consistent with findings of mitochondrial 
abnormalities in patient biopsies. We demonstrated that increased in vitro afterload 
augments sunitinib cardiotoxicity. Finally, we created microtissues from cardiomyocytes 
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derived from human pluripotent stem cells and found that afterload is required for 
sunitinib induced apoptosis at clinically relevant exposure concentrations. 
Our finding that afterload is a key mediator suggests that anti-hypertensive therapy may 
be important for avoiding eventual LV dysfunction in patients treated with sunitinib. 
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Chapter 1: Introduction  
  
The rise of small molecule inhibitors targeting receptor tyrosine kinases (RTKs) 
that regulate angiogenesis and proliferation has resulted in important gains in cancer 
survival.  However, many of these “targeted” therapies have unintended consequences on 
the cardiovascular system.  Sunitinib is a multi-targeted TKI that is used widely in the 
treatment of renal cell carcinoma, gastrointestinal stromal tumors, and neuroendocrine 
tumors and is currently under investigation in over 100 open clinical trials. Specifically, 
as it relates to sunitinib, hypertension occurs in 11-43% of patients and left ventricular 
(LV) dysfunction in 9.7%.  These toxicities, although often manageable, can result in 
dose delays, treatment interruptions, or dose reductions.  
Cardiovascular toxicity with sunitinib has been hypothesized to be a result of off-
target inhibition of RTKs required for normal physiologic function. Sunitinib, used in the 
treatment of many solid tumors, demonstrates inhibitory activity across a number of 
RTKs including: vascular endothelial growth factor receptors (VEGFR1-3), platelet 
derived growth factor receptor (PDGFR-B), FMS-like tyrosine kinase (FLT-3/CD135), 
the stem cell receptor c-kit (KIT/CD117), and 5' AMP-activated protein kinase (AMPK), 
all of which have been shown to be either cardioprotective during times of stress or 
important for maintaining cardiovascular homeostasis. However, the relative 
contributions of each of these factors remains poorly understood. In particular, the direct 
effects of increased afterload on cardiac function in the setting of sunitinib remain 
speculative. Given the established link between increased afterload and the eventual 
development of LV dysfunction, we hypothesized increased afterload will augment the 
cardiotoxic effects of sunitinib.  
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Testing the hypothesis that increased afterload exacerbates sunitinib toxicity 
would require a large in vivo clinical trial and substantial expense, and may face various 
ethical roadblocks if we were to have cohorts of patients with uncontrolled hypertension. 
Current in vitro cell culture and animal models suffer from limitations that minimize their 
usefulness for modeling human sunitinib cardiotoxicity. The overall goal of this thesis 
was to create a preclinical model of human sunitinib cardiotoxicity using an in vitro 
microtissue model in which 3D cardiac microtissues (CMT) from neonatal rat 
cardiomyocytes self-assemble on silicone (PDMS) cantilevers. We used this system to 
characterize sunitinib cardiotoxicity using metrics for cell viability, mitochondrial 
dysfunction and contractile function, and examined how these characteristics are 
impacted by sunitinib dose, treatment duration, and degree of loading. We also performed 
preliminary experiments using CMTs composed of human pluripotent (iPS) derived 
cardiomyocytes and compared our results to neonatal rat CMT results. 
The organization of this thesis is as follows: Chapter 2 provides background 
information on tyrosine kinase inhibitors and how we evaluate their cardiotoxic effects, 
such as hypertension and LV dysfunction, in a clinical setting. Next, we specifically focus 
on sunitinib, and discuss its observed cardiotoxic effects in patients and our current 
insights into the primary mechanisms governing sunitinib cardiotoxicity. We also discuss 
some of the limitations with current models being utilized to assess sunitinib 
cardiotoxicity. The final part of chapter 2 focuses on how we can take advantage of recent 
advances in human pluripotent stem cell derived cardiac cell types and tissue engineering 
to create novel preclinical models for evaluating drug induced cardiotoxicity.    
Chapter 3 describes the experimental methods utilized for this thesis. We included 
information about isolation and cell culture techniques for both neonatal rat cardiac cell 
types as well as information on human pluripotent culture and cardiac differentiation 
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methods. We also discuss microfabrication and seeding protocols for creating cardiac 
microtissues (CMTs). In the final part of this chapter, we discuss analytical methods used 
for detecting cell viability, cardiac function, and mitochondria function (membrane 
potential, ATP levels).  
 Chapter 4 discusses the in vitro model established to study sunitinib 
cardiotoxicity. Using the rat microtissue model, we characterized sunitinib cardiotoxicity 
in terms of its effects on cell viability and CMT function. We looked at caspase 3/7 
activation and late apoptosis/necrosis to characterize cell viability. When examining 
effects on cardiac function, we analyzed changes in tissue force generation (diastolic and 
systolic) as well as electrophysiology (spontaneous beating rate, excitation threshold, 
maximum capture rate). We assessed the dependence on these factors on sunitinib dose 
and/or treatment duration. 
 In Chapter 5 we focused on elucidating some of the mechanisms of sunitinib 
cardiotoxicity. As mentioned above, we hypothesized that increased afterload would 
augment sunitinib cardiotoxicity. We created microtissues under different degrees of 
afterload using CMT model by changing the material properties of the pillars, which 
serves as the major source of afterload, and assessed caspase 3/7 activation in response to 
sunitinib treatment. We also examined changes in mitochondria function in response to 
sunitinib. Specifically we looked at differences in mitochondrial membrane potential in 
rat cardiomyocytes, and evaluated the dependence of this response on treatment duration. 
To see how changes in mitochondria function affect downstream energy production, we 
also measured cellular ATP levels. Finally, we evaluated the ability of an AMPK 
activator to reverse sunitinib induced caspase activation.   
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 In Chapter 6 we show preliminary results with human CMTs created from 
pluripotent stem cells derived cardiomyocytes (iPS-CMs). We evaluate caspase 3/7 
activation with sunitinib treatment and compared our findings to rat CMTs. We also 
measured caspase 3/7 levels in human CMTs subjected to different degrees of afterload to 
determine whether increased afterload augments sunitinib cardiotoxicity in human cells.  
 Chapter 7 summarizes the results of the present work and discusses their clinical 
relevance. We also outline future research plans for this project.  
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Chapter 2: Background Information 
 
2.1 Tyrosine Kinase Inhibitors and their Cardiotoxic Effects 
2.1.1 Development of Tyrosine Kinase Inhibitors (TKIs) as Anti-Neoplastic Agents: 
Tyrosine Kinase Inhibitors (TKI’s) entered the drug landscape at a time when 
researchers were looking for more targeted therapies for treating cancer, as such drugs 
were predicted to have less overall toxicity compared to conventional anti-neoplastic 
treatments (anthracyclines, anti-metabolites) that were currently available on the market.  
Advances in genomics as well as our understanding of cell signaling networks allowed 
researchers to elucidate the differences between healthy and cancerous cells. From this 
body of research, receptor tyrosine kinases (RTK) emerged as a therapeutic target, as 
many cancers were found to be associated with erroneous activation of these receptors 
[Gschwind et al. 2004]. This finding was confirmed on the DNA level [Robinson et al. 
2000]. RTKs play a major role in signaling networks associated with normal cell function, 
regulating processes associated with growth and differentiation, and are present in most 
tissues [Lodish et al. 2000]. Because cancer is associated with erroneous activation of 
these receptors, anti-neoplastic drugs were targeted towards partially silencing these 
RTKs, and hence the class of TKI drugs was born. The amount of cancer research 
dedicated to identifying effective TKI’s has increased dramatically since 1970 (Figure 2.1 
panel A) [NCBI, PubMed].  
The first TKI to be approved by the FDA was tratstuzmab (Herceptin®, 
Genentech); a humanized mouse monoclonal antibody targeted against the human RTK 
epithelial growth factor 2 receptor (EGF2/ERbB2) in 1998 [Paul MK et al. 2004]. Its 
primary use was to treat metastatic breast cancer. Since the approval of tratstuzmab, there 
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have been 27 TKIs approved by the FDA for a variety of different solid tumors (breast, 
colon, renal, etc.) since 2001(Fig 2.1 panel B) [Wu et al. 2015].  
 
Figure 2.1: The rise of Tyrosine Kinase Inhibitors (TKIs). A) Article count of TKI 
research in field of cancer over time (NCBI, PubMed). B) Timeline of FDA approval of 
protein and lipid kinase inhibitors. Reprinted from Trends in Pharmacological Sciences: 
P. Wu et al, “FDA-approved small-molecule kinase inhibitors”, Volume 36 Issue 7, 422-
29, Copyright 2015 with permission from Elsevier. License no. 3980390063464 
 
TKI drugs can either be single-targeted or multi-targeted. Looking at equilibrium 
dissociation constants (Kd) across a number of different substrates is useful for 
determining TKI specificity, with lower Kd constants being associated with increased 
binding affinity. In the figure below the authors determined dissociation constants for 
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numerous chemotherapy agents across numerous kinases (Figure 2.2) [Fabian et al. 
2008]. Drugs like Lapatinib (labeled as GW-2016) only show binding affinity for a few 
substrates indicating a high degree of specificity. On the other hand, drugs like 
staurosporine and sunitinib (labeled as SU11248) have the ability to bind to numerous 
targets, giving them lower degrees of specificity. Multi-targeted TKIs with a low degree 
of specificity such as sunitinib have the potential to become problematic, as the drug may 
interfere with kinase activity required for normal physiological function, thus leading to 
unwanted side effects such as cardiotoxicity [Broekman et al. 2011]. Currently, there are 
over 300 open clinical trials [clinicatrials.gov] focused on TKI’s and tens of thousands of 
patients receiving these drugs, hence their impact will continue to grow, so it is important 
to identify any potential negative side effects associated with these drugs so we can 
maximize their use and safety. 
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Figure 2.2: Specificity profiles of various chemotherapy compounds.  A plot of 
dissociation constants (Kd) of chemotherapy agents against a variety of target molecules. 
[Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer Research 
UK: Nature Biotechnology, Miles A Fabian, William H Biggs, Daniel K Treiber, Corey E 
Atteridge, Mihai D Azimioara et al., “A small molecule kinase interaction map for 
clinical kinase inhibitors” Vol. 23 Issue 3:  Copyright (2008); License no. 
3979410866899] 
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2.1.2 Types of Cardiotoxicity  
 One major consequence of chemotherapy can be cardiotoxicity. Cardiotoxicity is 
defined as dysfunction relating to the heart (ischemia, arrhythmias, heart failure, 
myocarditis, pericarditis), as well as alterations in hemodynamics (hypertension, acute 
coronary syndrome) [Rodriguez 2015]. We will primarily focus our discussion on 
arrhythmias, hypertension, and heart failure as they are the most prevalent forms of 
chemotherapy induced cardiotoxicity observed in the clinic.  
 
2.1.2.1 Arrhythmias: 
Arrhythmias are defined as any abnormality in the heart’s electrical system that 
results in an abnormal heart rhythm. These electrical impulses may happen too quickly, 
too slowly, or erratically – causing the heart to speed up, slow down, or beat erratically 
[The American Heart Association Sept 2016]. The main consequence of this abnormal 
beating is ineffective pumping of blood to the rest of the body. While most arrhythmias 
are harmless, some can be life threatening, such as long QT syndrome, a condition that 
causes prolongation of the QT interval resulting from a mutation(s) in one or more ion 
channels (sodium, potassium, or calcium) [The American Heart Association Sept 2016]. 
In the context of drug development, identifying any changes in the QT interval is vital as 
a measure of the pro-arrhythmic potential of a candidate drug [FDA Center for Drug 
Evaluation and Research (CDER) 2005]. Pre-clinical studies utilizing mammalian cells 
(CHO, HEK293) transfected with the human Ether-à-go-go-Related Gene (hERG; 
potassium ion channel) and large animal models are widely utilized to assess the pro-
arrhythmic potential of drugs [FDA CDER 2005], but have their limitations as we will 
explain later. Later in the drug approval process, arrhythmias are closely monitored 
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during clinical trials with healthy and diseased patients. Despite these efforts, 
chemotherapy induced arrhythmias are still an issue today.  Table 2-1 gives a detailed list 
of the types of arrhythmias and which chemotherapy agents are associated with causing 
these arrhythmias [Tarmargo et al. 2015]. To summarize, atrial fibrillation occurs in 
patients taking alkylating agents, cisplatin, and anti-metabolites (7.9-10%, 12-32%, 0.55-
12% respectively). Taxanes have a high incidence of sinus bradycardia (slowing of heart 
beat), about 30% according to the National Cancer Institute [Tarmargo et al. 2015]. 
Treatment with anthracyclines carries a risk, about 24%, of premature ventricular 
contractions [Tarmargo et al. 2015]. As for tyrosine kinase inhibitors, many have been 
demonstrated to block hERG channel, however their effects on QT prolongation are mild 
(<15ms) and the overall occurrence of arrhythmias is low (<2%) [Tarmargo et al. 2015; 
Shah RR et al. 2014&2015]. Large effects on the QT interval (>500ms) have been 
observed in <2.3% of patients for the TKI sunitinib [Shah RR et al 2014&2015]. 
Additionally there have been only isolated cases of atrial fibrillation with TKI therapy 
[Tarmargo et al. 2015; Shah RR et al. 2014&2015].  In summary, arrhythmia disorders 
are often times a consequence of chemotherapy treatment, but depending on the agent, the 
type and risk of arrhythmias can vary significantly.    
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Table 2-1: Types of cardiac arrhythmias induced by chemotherapy drugs. [Original 
Source: Drug Safety, Cancer Chemotherapy and Cardiac Arrhythmias: A Review, 
Volume 38 Issue 2, 2015, Juan Tamargo.  Reproduced with permission from Springer: 
License no. 3979440363625]   
 
2.1.2.2 Hypertension and its Link to Cardiac Function 
Hypertension is a relatively common cardiovascular toxicity caused by 
chemotherapy. Hypertension is defined as a systemic blood pressure greater than 140/90 
mmHg. Increased blood pressure can cause damage to arteries, leading to long-term 
consequences including abnormal vasomotion, atherosclerosis, and ultimately result in 
inadequate blood flow to organs (heart, kidneys, brain) and increase the risk for 
myocardial infarction, kidney failure, and stroke [The American Heart Association Oct 
2016]. TKI’s are especially known for inducing hypertension, as many of these drugs 
were designed to inhibit angiogenesis, via vascular endothelial growth factor receptor 
(VEGFR) and/or platelet derived growth factor receptor (PDGFR) inhibition. Thus, TKIs 
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carry a high risk for causing vascular dysfunction and increased oxidative stress [Shah RR 
et al 2015; Chintalgattu et al. 2010; Di Siena et al. 2016; Zentilin et al. 2010]. Studies 
report an 11-43% incidence of hypertension with anti-angiogenic TKI therapy [Guverich 
et al. 2009]. These patients have a 7-8 fold increased relative risk for hypertension 
[Guverich et al. 2009]; thus blood pressure should be monitored during a patient’s 
treatment with TKI therapy. 
Increased blood pressure also has direct effects on the heart. The left ventricle of 
the heart, the “pump” responsible for ejecting blood into the aorta, must generate enough 
pressure to match circulating blood pressure in order for aortic valve to open and eject 
blood. Thus, during a hypertensive state, ventricles are required to generate more systolic 
(active) force. We use the term afterload to describe the external load the myocardium 
(heart) must overcome before shortening (ejection) can begin [Norton JM 2001]. 
Therefore hypertension causes increased afterload on the heart. This is significant because 
increased demands for force generation will also have effects on the amount of volume 
pumped out by the ventricle (stroke volume, SV) [Klabunde 2015]. Figure 2.3 (panel A) 
depicts what is known as the force-velocity relationship for cardiac muscle. When force is 
at a maximum, such as when the heart is under high degrees of afterload, contraction 
velocity is approaching zero. As the amount of afterload/force decreases, the velocity of 
contraction increases. Therefore if the ventricle is forced to pump harder, it can’t pump as 
quickly and less blood ultimately gets ejected, hence stroke volume decreases (Figure 2.3 
panel B) [Klabunde 2015]. If not compensated for, this would be a major problem as 
organs wouldn’t be receiving enough blood. Luckily hearts have another mechanism to 
compensate for decreased SV due to increased afterload. The increased volume of blood 
remaining in the ventricle due to the afterload increase will cause the ventricle to stretch 
more during filling process; this stretch on the ventricle is called preload. According to 
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the Frank-Starling mechanism, this increase in preload will lead to increase in stroke 
volume [Brady JM 1991]. Hence, increases in afterload can be partially compensated for 
by increases in preload. However, if a patient has defects in the Frank-Starling 
mechanism due to an underlying cardiovascular condition, a hypertensive (increased 
afterload) state could be lead to decreased cardiac output and left ventricular dysfunction, 
which I will be discussing in the next section [Fernandes-Silva et al. 2016; Ozkan et al. 
2011].  
 
Figure 2.3: Effect of Afterload on Cardiac Force Generation. A) Force-Velocity 
Relationship. B) Increased afterload decreases stroke volume (SV) which results in 
increased filling pressures (LVEDP) during next cardiac cycle. [Original Source: Richard 
E. Klabunde, CV Physiology 2015. “Cardiac Afterload” and “Cardiac Muscle Force and 
Velocity Relationship” www.cvphysiology.com ] 
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2.1.2.3 Left Ventricular (LV) Dysfunction 
The previous section already alluded to one mechanism for LV dysfunction, 
through hypertension and its resulting effects on the heart. There are a number of factors 
that can contribute to LV dysfunction both genetic and environmental. Chemotherapy 
treatment, for example, carries a risk of killing cardiac myocytes via apoptosis; this loss 
of cells puts more workload on the remaining cells. The ventricle chamber expands and 
dilates in an effort to normalize stresses, however ultimately normal cardiac output cannot 
be restored (Figure 2.4 panel A) and the patient develops heart failure. There are a 
number of additional factors contributing to development of heart failure such as 
sustained activation of neurohumoral systems that ultimately induce maladaptive changes 
in individual cardiac myocytes, inflammatory factors, myofibroblast 
differentiation/fibrosis, and changes in cardiac metabolism [Minguell ER 2004; Fan D et 
al. 2012; Kolwicz SC et al. 2013]. In the case of myocardial infarction or chemotherapy 
induced toxicity,  the initial loss of myocytes initiates a cascade of maladaptive 
remodeling that ultimately results in heart failure. Heart failure is usually classified by the 
severity of the patient’s symptoms. Figure 2.4 (panel B) shows the New York Heart 
Association’s (NYHA) heart failure classification system: 
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Figure 2.4: Progression of Heart Failure. A) Development of heart failure after 
hemodynamic overloading. [Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Cardiology (Ziad Taimeh, John Loughran, Emma J. Birks and Roberto 
Bolli, “Vascular endothelial growth factor in heart failure” Vol. 10 Issue 9, Copyright 
(2013). License No. 3979440910127] B) NYHA Classification of Heart Failure. [Source: 
ReliantHeart Inc., “Left Ventricular Dysfunction.” http://reliantheart.com/left-ventricle-
dysfunction/]  
 
The overall incidence of all-grade and high-grade chronic heart failure associated 
with anti-angiogenic (VEGFR) TKIs was 3.2 % (95 % CI 1.8–5.8) and 1.4 % (95 % CI 
0.9–2.3) [Shah RR et al. 2015], respectively. A meta-analysis of randomized phase II and 
III clinical trials of patients with solid tumors receiving sunitinib, axitinib, cediranib, or 
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regorafenib reported a relative risk of all-grade cardiac dysfunction to be 2.36 (95 % CI 
0.95–5.87; p = 0.06). [Shah RR et al. 2015] 
 
2.1.2.4 Distinguishing Direct and Indirect Mediators of TKI Induced Cardiotoxicity 
The previous sections discussed the various ways in which cardiotoxicity from 
chemotherapy treatment can present itself (arrhythmias, hypertension, and LV 
dysfunction). What isn’t discussed or studied as frequently is whether cardiotoxicity is 
due to: 1) intrinsic toxicity of the chemotherapy agent, or 2) indirect effects, such as 
toxicity to a different organ system. In the case of TKIs, many induce hypertension due to 
their anti-angiogenic properties, and, as I discussed above, hypertension can cause LV 
dysfunction. However, depending on the drug’s RTK specificity, the drug could also be 
directly toxic to cardiac myocytes by disrupting their own RTK dependent pathways, 
which can result in LV dysfunction. So a major question arises; what are the relative 
contributions of hypertension (i.e. increased afterload) and intrinsic toxicity to LV 
dysfunction? We will attempt to answer this question in Chapter 5 of this dissertation, 
which explicitly looks at toxicity induced by sunitinib under varying degrees of afterload. 
2.1.3 Diagnosing and Monitoring Cardiotoxicity in the Clinic  
Despite the prevalence of chemotherapy-induced cardiotoxicity, there are 
currently no specific guidelines for treating and monitoring it [Albini et al. 2010]. 
Nevertheless, the field of cardio-oncology has emerged in response to the complex 
decision making necessary to balance the benefits and risks associated with treating 
cancer. Cardio-oncologists rely on a battery of tests (imaging, biopsy, biomarkers in 
blood) in order to formally diagnose patients with chemotherapy induced cardiotoxicity. 
This section will review some of these methods and how they relate to diagnosis criteria. 
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2.1.3.1 Methods for Diagnosing Chemotherapy Induced Cardiotoxicity 
Endomyocardial biopsy remains the most sensitive method for detecting 
cardiotoxicity, although it is also the most invasive method. With this method, small 
samples of heart tissues are analyzed for distortions in myocyte organization. 
Electrocardiograms and Echocardiograms (2D or 3D) are utilized more often in the clinic 
as they are far less invasive. Electrocardiograms can reveal dysfunction in the heart’s 
electrical activity, and thus are useful for detecting arrhythmias, which can be side effects 
of certain chemotherapy regimens. Echocardiograms, on the other hand, are useful for 
looking at diastolic (filling) and systolic (pumping) function of the heart and the 
morphology of the heart’s chambers and valves. Echocardiograms are frequently used to 
calculate and monitor the ejection fraction of the left ventricle (LVEF); which represents 
the fraction of blood pumped out of the heart relative to the amount that of blood in the 
chamber at the end of filling (systolic function). Normal LVEFs typically range from 
55%-65%, and significant decreases (>10%) over time are associated with LV 
dysfunction. One major disadvantage of looking at LVEF is that declines often times do 
not occur until later stages of cardiotoxicity. Ideally we would like to identify 
cardiotoxicity at its earliest stages. [Pizzino F et al. 2014; Sawaya H et al. 2012]. 
Next, we will discuss some emerging technologies for early detection of 
cardiotoxicity (i.e. precedes declines in LVEF). One of these techniques is called speckle-
tracking imaging. This method focuses on analyzing the 3D twisting and torsion 
deformations that occur during contraction by tracking natural acoustic and inference 
patterns called “speckles” within an ultrasonic window. The deformation between 
speckles within a region is calculated, obtaining a value referred to as strain. The velocity 
of strain is defined as strain rate. Several studies have looked at variations in strain and 
strain rate in patients receiving chemotherapy and found that these values are early 
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predictors of eventual declines in LVEF. Magnetic Resonance imaging can also be 
utilized for tissue characterization to detect things like early fibrosis by administering 
gadolinium and looking for late gadolinium enhancement. Late gadolinium enhancement 
is when a tissue presents slow contrast wash-out, which is usually a sign of scar 
tissue/fibrosis. Early alterations of late gadolinium enhancement have been described in 
chemotherapy-treated patients and are predictive of declines in LVEF. [Pizzino et al 
2014].  
The final technique we would like to discuss is the use of biomarkers. The 
presence of cardiac specific proteins such as cardiac troponin is indicative of cardiac 
damage [Yu EF et al 2016]. Elevations in troponin levels are usually used to diagnose 
myocardial infarction (heart attacks). Troponin levels measured after chemotherapy 
treatment have been shown to be predictive of later cardiotoxicity, as has 
myeloperoxidase, with the combination of these two biomarkers representing the highest 
risk for future cardiac dysfunction [Pizzino et al 2014]. However, these studies were 
conducted with small patient populations and larger studies are required to confirm these 
results. Biomarker testing is relatively non-invasive and easy to perform and analyze.  
In summary, there are a variety of methods for detecting cardiotoxicity, with some 
new emerging technologies that may allow for detecting very early signs of 
cardiotoxicity, specifically those that precede LVEF decline. Ideally, cancer patients 
should get testing done before treatment to get baseline levels of biomarkers (troponin) 
and LVEF and have these quantities monitored during and after treatment [Yu EF et al. 
2016]. This is especially important if the patient has a previous history of cardiovascular 
disease, as it has been shown that patients who experience the most adverse cardiac 
outcomes following chemotherapy treatment are ones who had underlying cardiovascular 
disease before treatment [Albini et al. 2010]. 
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2.1.3.2 Diagnosis Criteria for Chemotherapy Induced Cardiotoxicity 
The Cardiac Review and Evaluation Committee (CREC) defines chemotherapy-
induced cardiotoxicity as the presence of at least one of the following elements: [Pizzino 
et al. 2014] 
1. Cardiomyopathy characterized by a decrease in LVEF 
2. Symptoms of congestive heart failure (see NYHA guidelines) 
3. Associated signs of congestive heart failure such as but not limited to: 
tachycardia or S3 gallop. 
4. Decline of LVEF of at least 5% to below 55% with accompanying signs of 
congestive heart failure; or a decline of LVEF of at least 10% to below 
55% without accompanying symptoms. 
2.1.3.3 Categories of Chemotherapy Induced Cardiotoxicity 
 Cardiac dysfunction due to chemotherapy can be divided into three categories: 1) 
acute, 2) subacute, or 3) chronic. Acute or subacute cardiotoxicity can develop any time 
from the start of treatment up to 2 weeks after the completion of chemotherapy. Chronic 
cardiotoxicity, on the other hand, might not present itself until almost a year after the 
completion of treatment (early cardiotoxicity) or more than one year after treatment (late 
cardiotoxicity). This further reinforces the notion that patients should be monitored 
(biomarkers, LVEF measurements), not just during treatment, but also for a significant 
amount of time after treatment. Additionally, methods for pre-treatment testing with 
predictive value may be worth developing [Albini et al. 2010]. 
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2.2 Sunitinib Malate: A Tyrosine Kinase Inhibitor with Cardiotoxic 
Effects 
 
2.2.1 Mechanism of Action 
Sunitinib (SU11248) was originally developed by a small biopharmaceutical 
company named SUGEN, after three of their other PDGF inhibitors failed in clinical trials 
(1994-1999). Two acquisitions later, sunitinib became the property of Pfizer who finished 
phase III clinical trials for the drug.  Eventually, the drug was approved in January 2006 
for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumors 
(GIST) [NIH/National Cancer Institute]. Originally designed as a PDGFR inhibitor to 
target tumor angiogenesis, sunitinib actually exhibits inhibitory behavior across a number 
of RTKs associated with angiogenesis such as VEGFR1-3, PDGFR(a, b), FMS related 
tyrosine kinase (FLT-3), and the stem cell receptor KIT [O’Farrell et al. 2003; Faivre et 
al. 2007]; . Compared to similar TKIs available at the time, such as Gleevec (imatinib), 
sunitinib had more of a multi-targeted effect [Fabian et al 2008]. This attribute could 
explain why sunitinib successfully treated tumors that were resistant to Gleevec [Demetri 
et al. 2006]. Currently, more than 100,000 people have been treated with sunitinib, and 
there are over 100 open clinical trials with this drug [clinicaltrails.gov]. This fact stresses 
the notion that we need to better our understanding of sunitinib cardiotoxicity, as even 
more people will be treated with this drug in the future. 
2.2.1 Clinical Incidences of Sunitinib Cardiotoxicity 
 Early incidences of cardiotoxicity were observed during phase I B trials with 
leukemia (AML) patients when researchers were trying to determine dosage and safety. In 
a trial of 16 patients given sunitinib (50mg or 75mg dose), the 2 patients given the 75 mg 
dose experienced grade 4 hypertension and one patient developed heart failure (after 
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suffering a myocardial infarction) and died “due to cardiac insufficiency”. The authors 
commented that they believe this death could have been related to sunitinib treatment. As 
a result of this cardiotoxicity, the authors concluded that 50mg is the maximum tolerable 
dose for these patients. [Fiedler et al. 2005] 
 Cardiovascular toxicity of sunitinib was also reported during numerous Phase III 
clinical trials. In one study, GIST patients taking 50mg of sunitinib per day reported cases 
of Grade 1/2 (15 patients/8%) and Grade 3 hypertension (6 patients/ 3%). There were no 
reported cases or heart failure with 50mg dose [Demetri et al. 2006]. However in two 
separate phase III trials, there were reports of LV dysfunction. Telli and colleagues 
reported that 7 out 48 enrolled patients experienced grade 3 or 4 symptomatic LV 
dysfunction anywhere from 22 to 435 days after treatment. Three of those patients 
continued to experience heart failure even after sunitinib was removed and they began 
treatment for heart failure. The authors noted that a history of cardiovascular disease was 
a major factor in this result [Telli et al 2008]. Along these lines, Hall and colleagues 
published results from a phase III trial with sunitinib where they defined the number of 
patients with either hypertension or LV dysfunction, both before and after treatment. 
These results are plotted below in Figure 2.5. [Hall et al. 2013]. 
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Figure 2.5: Hypertension and LV Dysfunction following treatment with sunitinib. 
Number of patients with various grades (0-4) of hypertension (left) and/or LV 
Dysfunction (right) before (blue) and after (red) treatment with sunitinib. Figures were 
created using data from Table 2 of G. DiLorenzo et al. Ann. Oncol. 2009. 
 
This figure shows a general trend towards worsening degrees of both hypertension 
and LV dysfunction following sunitinib treatment. These studies as a whole not only 
demonstrate the potential for adverse cardiovascular outcomes with sunitinib, they also 
serve as an example of how factors like medical history can play a role in whether or not 
a patient will develop cardiotoxicity. These confounding factors highlight the need for 
more standardized screening methods for drug toxicity in human cells. Chapter 4 
discusses the creation of a preclinical tissue culture platform that can be combined with 
human cells to assess the toxicity of candidate drugs. 
2.2.1 Insights into the Molecular Mechanisms of Sunitinib Cardiotoxicity 
2.2.1.1 Animal and In Vitro Cell Culture Study Design  
Following reports of cardiotoxicity during human clinical trials, researchers aimed 
to gain a better understanding of 1) sunitinib toxicity at the cardiomyocyte level and 2) 
the underlying mechanisms governing this toxicity. One obvious cause of cardiotoxicity 
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could be off-target inhibition of angiogenesis in the heart. As mentioned earlier, sunitinib 
can inhibit a variety of TKI’s associated with angiogenesis (VEGFR1-3, PDGFR-A/B, 
FLT-3, and the stem cell receptor KIT). It is widely recognized that many, if not all, of 
these receptors are critical for maintaining cardiovascular homeostasis and/or protecting 
the heart during times of increased stress. In this next section I will discuss studies that 
aimed to elucidate effects of sunitinib on cardiomyocytes and identify some key signaling 
pathways involved in this response.  
The majority of these studies employed either adult mice or primary rat 
cardiomyocyte cell cultures. One study I will discuss utilized human atrial muscle strips. 
The doses of sunitinib typically utilized in these studies ranged from 0.1-250µM (mostly 
1-10µM range) from cell culture studies and 20mg/kg -100 mg/kg per day for animal 
studies. To put these doses into perspective, a 50 mg/day treatment regimen for a patient 
results in average sunitinib concentrations in the blood (plasma) at around 0.1-0.2µM with 
peak plasma concentrations at 2µM sunitinib [Faivre et al. 2005; Harvey and Leinwand 
2015]. In view of this, some experiments appear to utilize doses that are outside the 
physiological range.  Some of the metrics used for characterizing sunitinib toxicity in 
these include:   
1. Apoptosis: Caspase 3/7, 9 activation, TUNEL, cytochrome C release 
2. Cell Viability: LDH release,  mitochondrial morphology 
3. Metabolism and Energetics: ATP levels, lipid drop formation 
4. Functional: EF, blood pressure, calcium transients, contractile reserve 
Alterations in cell signaling were also examined in many of these studies. Those findings 
will be discussed later in this section.  
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2.2.1.2 Results from Animal Studies: Insights into Afterload as a Possible Mediator of 
Sunitinib Cardiotoxicity 
In studies using adult mice treated with sunitinib, mitochondrial morphology 
changes (swelling) could be observed with as little as 10 mg/kg per day of sunitinib [Chu 
et al. 2007]. Cardiac myocyte hypertrophy was observed with 25 mg/kg per day sunitinib, 
however neither hypertension nor LV dysfunction were observed at this dose. However, if 
phenylephrine (PE) was administered concurrently with sunitinib (25 mg/kg), there were 
signs of cardiomyocyte apoptosis, measured by caspase activation [Chu et al. 2007; 
Kerkela et al. 2007]. This is an interesting finding as PE can increase blood pressure, 
which would increase the amount of afterload on the heart. This result suggests that 
sunitinib toxicity might be dependent on mechanical loading conditions in the heart. 
However, PE has also been shown to act directly on cardiac myocytes by inducing 
myocyte hypertrophy [Clerk et al. 1998]. Therefore, while PE isn’t the best choice for 
regulating afterload, nevertheless these results are interesting. Finally, doses of sunitinib 
exceeding 40 mg/kg per day have been shown to induce LV dysfunction [Khakoo et al. 
2013]. The authors observed decreases in EF as well as contractile reserve. Additionally, 
hearts treated with sunitinib suffered greater dysfunction after undergoing TAC (trans-
aortic constriction), an intervention that greatly increases the amount of afterload 
experienced by the heart (referred to as “pressure overload”) [Khakoo et al. 2007]. Again, 
we see signs that sunitinib toxicity may be regulated by afterload. Like PE administration, 
TAC has its disadvantages as a method for increasing afterload because it is pathologic 
independent of sunitinib treatment. In Chapter 5, we will discuss how we can use our 
microtissue platform to assess the contribution of afterload to sunitinib cardiotoxicity. 
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2.2.1.3 Results from Primary Rat Cell Culture Studies 
In studies that utilized doses of sunitinib around 0.1-10µM, cytochrome-C and 
caspase 3/7 activation were observed indicating rapid apoptosis of neonatal rat cardiac 
myocytes. Maayah and colleagues report decreases in cell viability of 35%, 50%, and 
70% in cultures treated with 25µM, 50µM, and 100µM sunitinib respectively [Maayah et 
al. 2014]. There were also reported decreases in ATP levels as well as mitochondria 
membrane potential [Maayah et al. 2014]. The effect on cell energetics prompted Kerkela 
and colleagues to investigate dysregulation of AMPK (5' AMP-activated protein kinase) 
as the culprit. In general, AMPK is activated during times of energy depletion and helps 
maintain ATP levels by restricting energy utilization and increasing energy production. 
Kerkela et al. discovered that sunitinib can directly inhibit the activity of AMPK (i.e. 
phosphorylation of acetyl CoA carboxylase, p-ACC). This could contribute to decreased 
ATP levels in cardiac myocytes treated with sunitinib [Kerkela et al. 2009]. 
In addition to affecting viability and energetics, changes in myocyte function were 
associated with sunitinib treatment. Rainer and colleagues reported that 1.87µM sunitinib 
was sufficient to negatively affect sarcomere shortening and reduce calcium transients in 
isolated adult rat cells [Rainer et al. 2012]. As a whole these studies suggest that sunitinib 
negatively affects cardiomyocyte energetics via inhibition of AMPK, viability, and 
function. However many studies were performed using sunitinib levels outside the range 
of concentrations that are clinically relevant. 
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2.2.1.4 Results from Human Muscle Strip Study 
In addition to examining sunitinib toxicity in single adult mouse myocytes, Rainer 
and colleagues also assessed toxicity in muscle strips from the right atrium of patients. 
This part of their study stands out because it’s the only set of in vitro experiments 
utilizing adult human heart tissue. Muscle strips are difficult to obtain and have very high 
metabolic demands and unfortunately most experiments can only last for 24hr before 
muscle strips fail. Hence muscle strips do not serve as strong pre-clinical model for drug 
toxicity. Nevertheless, this study serves as model of relevant human biology and its 
results guided the design of our own functional experiments in rat cells. Less than 30 min 
of treatment with 1.87µM and 18.7µM sunitinib was sufficient to affect active force 
generation (decreased by 8% and 15% respectively) by muscle strips with no effect on 
diastolic forces. This finding helps to validate observations of LV dysfunction in human 
patients treated with sunitinib. [Rainer et al. 2012] 
 
2.2.1.5 Summary and Study Limitations 
In summary, the literature provides evidence that sunitinib can lead to LV 
dysfunction and cellular apoptosis, as well as depletion of ATP stores and mitochondrial 
dysfunction. However, the results presented here are highly dependent on the dose and 
duration of sunitinib treatment. There exists a need for more studies aimed specifically at 
characterizing the effects of sunitinib dose and duration on cardiotoxicity. Additionally, 
animal studies reveal a possible contribution of afterload to sunitinib cardiotoxicity, 
however better methods for controlling afterload are needed as current methods, such as 
PE and TAC, can have off-target effects on myocytes. Finally, there is only a single study 
examining sunitinib cardiotoxicity in isolated human tissues. Moreover, this study is 
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limited by the use of atrial (rather than ventricular) tissue and by relatively high doses of 
sunitinib treatment. This thesis will aim to address both of these shortcomings in the 
literature. 
 
2.3 Utilizing Human Pluripotent Derived Cardiomyocytes and Tissue 
Engineering Methods as Models for Detecting Sunitinib Induced 
Cardiotoxicity 
 
2.3.1 Establishing Standardized, Relevant Screening Methods for Predicting 
Cardiotoxicity 
The previous sections have revealed significant shortcomings in our 1) ability to 
predict or identify sunitinib induced cardiotoxicity its early stages and 2) biologic 
understanding of mechanisms behind sunitinib’s cardiotoxic effects. Current preclinical 
models are not well equipped to address these concerns [Astashkina et al. 2012]. CHO 
cells transfected with hERG channels are poor reductionist models of cardiac myocytes 
due to the lack of any contractile apparatus and complex ion channel network [FDA 
CDER 2005]. Animal models suffer from interspecies differences in cardiac biology, 
which are well documented and cannot be ignored [Seok et al 2013; Houser et al. 2012]. 
Developing robust preclinical models of sunitinib cardiotoxicity would allow us to begin 
addressing both issues. A good preclinical model would: 1) utilize human cell inputs; 2) 
permit control over cellular, biochemical, extracellular matrix (ECM), and mechanical 
cues and 3) provide functional readouts that can be used as metrics for toxicity. This 
section will outline how we can derive suitable human cardiac cell sources and utilize 
current tissue engineering methods as an in vitro testing platform. 
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2.3.2 The Rise of Human Cardiac Cell Sources from Pluripotent Stem Cells 
2.3.2.1 Advances in Cardiac Differentiation from Human Pluripotent Stem Cells 
Given the complexity of the human heart, differentiating human pluripotent stem 
cells (hPSCs), such as induced pluripotent (iPS) or embryonic stem (ES) cells, into 
cardiac cell types presented major challenges for researchers (see Figure 2.6 for an 
overview). Cardiac development is a complex interplay of various signaling pathways 
that are activated at specific time points during development [LaFlamme et al. 2011]. 
Researchers Gordon Keller and Charles E. Murry were among the first integrate this idea 
into their research. They identified Bone Morphogenic proteins (BMPs), specifically 
BMP-4, and Activin-A (nodal TGF-Beta pathway) as pivotal molecules for mesoderm 
determination, a critical step in cardiogenesis. [Kattman et al. 2011; Lian et al. 2013] 
 
Figure 2.6: Complexity of Cardiac Differentiation during development.  Various 
signaling pathways involved in the differentiation of pluripotent stem cells to cardiac 
myocytes. [Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: Nature, Michael A LaFlamme and Charles E Murry, “Heart Regeneration” 
Vol. 473 Issue 7347, Copyright 2011: License no. 3984420749070] 
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Murry and Keller’s differentiation protocols often times called for numerous 
growth factors supplemented in expensive basal media such as StemPro®. Thus their 
differentiation strategies were not cost-effective when it came to scaling up production of 
hPS-CMs [Kattman et al. 2011]. The Wu lab at Stanford developed a more cost effective 
strategy for creating a chemically defined media that produced highly pure (>80%) 
cultures of human cardiomyocytes that is increasingly used today. The protocol calls for 
fewer growth factors, as well as a more cost effective basal media (RPMI 1640). 
Furthermore, this differentiation protocol was successful on a number of iPS cell lines, 
despite genetic differences between the cell lines. Many of the human experiments 
conducted in this work utilized this differentiation method and will be discussed in more 
detail in later sections. [Burridge et al. 2014]  
 
2.3.2.1 Differences Between hPS-CMs and Adult Human Cardiomyocytes 
To utilize hPS-CMs for drug screening, ideally we would like these cells to 
exhibit a phenotype resembling that of an adult cardiomyocyte. However, despite 
advances in CM differentiation and maturation methods, hPS-CMs do not exhibit many of 
the characteristics of an adult myocyte. These cardiomyocytes are postulated to behave 
more like fetal cardiomyocytes. Yang et al. highlighted many of these differences in a 
recent review article; and the many differences are highlighted below (Table 2-2). [Yang 
et al. 2014] 
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Table 2-2: Differences between adult cardiomyocytes and hPS-CMs.  Immature 
Cardiomyocytes, such as hPS-CMs, do not display the same behaviors as adult human 
cardiomyocytes. [Adapted by permission from Wolters Kluwer: Circulation Research, 
Xiulan Yang, Lil Pabon, Charles E. Murry, “Engineering Adolescence” Vol. 114 Issue 3, 
Copyright 2014: License no. 3984421278291] 
 
While there are various differences amongst fetal and human cardiomyocytes, 
hPS-CMs still hold great potential for studying human cardiac diseases and for drug 
screening. However, investigators must realize that certain biological questions are not 
suitable to answer with hPS-CMs because they don’t exhibit that particular adult 
phenotype. Some examples include: changes in metabolism with heart failure and 
studying inotropic responses; this also must be kept in mind for determining metrics for 
drug induced cardiotoxicity.  However, hPS-CMs remain useful to for determining 
whether a drug is intrinsically toxic (i.e. induces apoptosis, necrosis) [Burridge et al 2016; 
Clements et al. 2015; Gilchrist et al 2015]. It is for that reason we sought to continue to 
utilize hPS-CMs in some of our experiments presented in Chapter 6. 
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2.3.2.2 Creating Patient-Specific hPS-CMs for Predictive Toxicology 
hPS-CMs not only serve as a reliable human cardiac cell source, they also have 
the potential to allow for an “individualized medicine” approach to predict cardiotoxicity, 
specifically, creating patient-specific hPS-CMs and screening them with compounds to 
help predict cardiotoxic responses. This is especially useful for patients with a known 
genetic mutation. We can re-program their somatic cells into an iPS cell line, differentiate 
these cells into hPS-CMs, and study their responses in vitro (Figure 2.7 panel A). 
Carvajal-Vergara and colleagues were able to create hPS-CMs with patients with 
LEOPARD syndrome, a mutation in the Ras-MAPK pathway, which is known to cause 
hypertrophic cardiomyopathy. The authors compared wild-type to LEOPARD hPS-CMs 
and found that the latter cell type had characteristics of hypertrophy such as increased cell 
size and increased NFAT4 (Nuclear factor of activated T-cells 4) localization to the 
nucleus [Carvajal-Vergara et al. 2010]. In a separate study, Hinson and colleagues 
examined the role of Titin mutations with hPS-CMs derived with patients with a specific 
mutation. They found that the cells with the mutation exhibited lower twitch force 
compared to wild-type hPS-CMs [Hinson et al. 2015]. Thus the ability to create hPS-CMs 
from patients with an altered genetic background can provide helpful insights into 
consequences of certain mutations on cardiomyocyte function. This idea can be extended 
to include studying how certain mutations will affect how a patient responds to a certain 
drug. 
In addition to creating hPS-CMs from patients with altered genetic backgrounds, 
we have also gained the ability to genetically edit iPS cells using newly developed Cas9 
technology and create hPS-CMs from these cells [Musunuru 2013; Strong et al. 2017]. 
Genome editing allows us to either create new mutations or correct existing mutations and 
examine phenotypic responses (Figure 2.7 panel B). [Musunuru 2013] 
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Figure 2.7: Comparison of two methods for disease modeling using hPS-CMs. A) 
Reprograming somatic cells from healthy and diseased patients into iPSCs and 
differentiating them into hPS-CMs. B) Genome editing of wildtype iPS or iPS with 
mutation to correct or mutate genes. [Figure adapted under the terms of the Creative 
Commons Attribution License: Disease Models & Mechanisms, Kiran Musunuru, 
“Genome editing of human pluripotent stem cells to generate human cellular disease 
models.” Vol 6: pgs. 896-904: Copyright 2013] 
 
Therefore, we can compare two cell lines that are genetically identical except for 
the presence or absence of a mutation. Hinson and colleagues also performed such 
experiments in their study; they created multiple iPS cell lines with different Titin 
mutations. They found that different mutations led to varying degrees of decreased force 
generation by cardiomyocytes created from these lines [Hinson et al. 2015]. Similar to 
creating iPS cells using patients with a genetic background, genome editing is a valuable 
tool for gaining insights into functional consequences of mutations and has the potential 
to provide us with more “informed” pre-clinical models for drug testing. 
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2.3.2.3 Studying Sunitinib Toxicology using hPS-CMs 
A limited number of studies have begun assessing the cardiotoxicity of sunitinib 
using hPS-CMs. Many of these studies utilized a commercially available hPS-CM source 
manufactured by Cellular Dynamics Inc. In one study Cohen and colleagues found that 
31µM sunitinib completely depleted ATP levels, and induced LDH release and caspase 
activation [Cohen et al. 2011]. In a separate study, Doherty and colleagues found that as 
little as 625nM sunitinib can cause disruptions in normalized beating rate, and 10µM 
sunitinib leads to a complete arrest of beating [Doherty et al. 2013]. Some major 
limitations with these studies are: 1) the use of non-physiological concentrations of 
sunitinib, specifically in the Cohen study; 2) no assessment of effect of afterload on 
toxicity; and 3) experiments were performed in flat, 2D cultures. Regarding the latter, 
culturing cells on rigid, flat substrates is clearly structurally and mechanically non-
physiologic. 2D culture is known to cause morphologic changes such as distortions of 
sarcomere organization and impose a non-physiologic amount of preload and afterload on 
cells, which will inherently negatively affect their function [Soares et al. 2012]. In the 
next section, we will go over alternate methods for culturing cells using current tissue 
engineering methods, and argue that these tissue culture models serve as better platforms 
for pre-clinical drug screening on cells such as hPS-CMs. 
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2.3.3 Utilizing Tissue Engineering Models as Cell Culture Platforms for Drug Screening 
2.3.3.1 Design Criteria for Tissue Culture Models and Limitations with Conventional 
Methods 
Even with the right type of cells, a suitable tissue culture platform is a necessity 
for improving current drug screening methods. An ideal platform would permit control 
over cellular, biochemical, and mechanical inputs so we can assess the relative 
contributions of each parameter [Ma et al. 2016; Ogle et al. 2016; Zhao et al. 2016]. 
Additionally, the platform would allow for making multiple measurements of tissue 
function. In the case of screening for cardiotoxicity, some examples of important 
functional assessments would include force generation and action potential peaks and 
kinetics. Current tissue culture platforms such as 2D flat cultures and animal models are 
inherently limited in their ability to control one of more of the design criteria listed above, 
and 2D culture platforms in particular are limited in their ability to provide functional 
data, such as force generation. Advances in the field of cardiac tissue engineering have 
resulted in improved strategies that combine the advantages of 2D in vitro culture and 
animal models to create a platform that fits the design criteria above. In this section we 
will outline some of these advances and discuss how they can be utilized for improving 
drug screening.  
 
2.3.3.2 Engineered Tissues Display Hallmarks of Cardiac Physiology 
Engineered tissues consist of cells combined with some kind of natural or 
synthetic ECM that are seeded on millimeter scale or micron scale platforms. For 
example, cells can self-assemble on a set of pillars/cantilevers or have their adhesion 
guided by engineering material properties (micropatterning, 3D printing, etc.) to control 
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cellular alignment (Figure 2.8). [Cashman TJ et al. 2016; Boudou et al. 2012; Lind et al. 
2016] 
 
Figure 2.8: Generating Engineered Cardiac Tissue. A) Human engineered heart tissue 
formed between two pillars. [Adapted by permission from Creative Commons Attribution 
license; Original Article: Cashman TJ et al. “Human Engineered Cardiac Tissue Using 
Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-mediated 
Hypertrophic Cardiomyopathy.” PLOS One 2016; 11:e0146697.]  B) Microgrooves guide 
cardiomyocyte alignment using topographical features. [Reprinted by permission from 
Macmillan Publishers Ltd: Nature Materials, Johan U. Lind, Travis A. Busbee, Alexander 
D. Valentine, Francesco S. Pasqualini, Hongyan Yuan, Moran Yadid, “Instrumented 
cardiac microphysiological devices via multi-material three-dimensional printing” 
Advance Online Publication, Copyright 2016: License no. 3984441121068] 
  
Engineered tissues can be electrically stimulated to give readouts of force and 
action potential waveforms (Figure 2.9 panels A, D). These tissues can also respond 
appropriately to the calcium blocker verapamil and beta-adrenergic agonist isoproterenol 
(Figure 2.9 panel B) [Lind et al. 2016]. Additionally, various authors have argued that the 
cells themselves can mature within these platforms [Tiburcy et al 2011]. Figure 2.9 (panel 
C) demonstrates how NRCMs can adopt a more adult-like morphology when being 
cultured in engineered heart tissue (EHT). 
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Figure 2.9: Engineered Tissues Recapitulate Aspects of Cardiac Physiology. A) 
Neonatal rat cardiomyocytes in engineered tissues decrease their generated stresses (y-
axis on plots) in response to increasing concentrations of the calcium channel blocker 
verapamil. B) Similarly, hPS-CMs respond to the β-adrenergic agonist isoproterenol by 
augmenting developed stresses.  [Reprinted by permission from Macmillan Publishers 
Ltd: Nature Materials, Johan U. Lind, Travis A. Busbee, Alexander D. Valentine, 
Francesco S. Pasqualini, Hongyan Yuan, Moran Yadid, “Instrumented cardiac 
microphysiological devices via multimaterial three-dimensional printing” Advance 
Online Publication, Copyright 2016: License no. 3984441121068]. C) NVRMs cultured 
in EHTs undergo advanced maturation, adopting morphologies resembling the adult 
phenotype. [Adapted by permission from Wolters Kluwer: Circulation Research, Malte 
Tiburcy et. al “Terminal Differentiation, Advanced Organotypic Maturation, and 
Modeling of Hypertrophic Growth in Engineered Heart Tissue” Vol. 109 Issue 10, 
Copyright 2011: License no. 3984450925448]. D) Action Potentials generated by EHTs 
composed of hES-CMs. [Figure adapted under Creative Commons Attribution license: 
PLOS ONE, Sebastian Shaaf et. al, “Human Engineered Heart Tissue as a Versatile Tool 
in Basic Research and Preclinical Toxicology” 2011. 
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2.3.3.3 Using Engineered Tissues to Study the Contribution of Cellular, Biochemical, and 
Mechanical Microenvironments on Tissue Function 
 One major design criterion highlighted above was that an ideal drug screening 
platform should permit control over cellular, biochemical, and mechanical inputs. 
Understanding how a cell’s response to a drug is influenced by these factors will 
important for maximizing the effectiveness and safety of new candidate drugs [Ma et al. 
2016]. Many engineered tissue models permit control over one or more of the factors 
listed. This section will discuss some of these attributes and explain their importance. 
2.3.3.3.1 Cellular Inputs 
Heart tissue is not just composed of cardiac myocytes; there are also non-
myocytes such as fibroblasts and vascular cells (endothelial and smooth muscle) 
present. Previous works have demonstrated the important role these non-myocytes 
play in maintaining cardiac homeostasis [Tian et al. 2012]. Hence, tissue 
engineers must decide what non-CM cell types to incorporate and at what ratio. 
Early work with EHT utilizing neonatal rat heart isolations found that tissues 
made from the “native” mix of heart cells generated higher diastolic and systolic 
forces and were more sensitive to calcium compared to EHTs composed of CM 
enriched cultures [Naito et al. 2006]. In a separate study using neonatal rat cells, 
Radisic and colleagues found that not only the presence of fibroblasts impacted 
tissue function, but also the order in which cells are seeded [Radisic et al. 2008]. 
The authors found that pre-seeding tissues with fibroblasts and seeding CMs later 
created tissues with better tissue shortening (analogous to force generation), better 
elongation of CMs, and more electrical sensitivity. In a study utilizing human ES-
CMs, Zhang and colleagues found that within the range of 45%-90% CMs, the 
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active force generated per CM actually decreased as purity increased, suggesting 
that the non-myocyte fraction played an important role in hES-CM maturation 
within tissues [Zhang et al. 2013]. In summary, cellular factors are important 
determinates of tissue function, with non-myocytes being key players that should 
be included in engineered tissues.   
 
2.3.3.3.2 Biochemical Inputs 
Biochemical inputs clearly modulate cardiac structure and function. An advantage 
of in vitro systems is the ability to selectively adjust these inputs. In contrast, 
animal models suffer from a relative lack of control over biochemical factors. 
Specifically, the target tissue will also be influenced by factors secreted by other 
organ systems, which could confound results. The in vitro nature of engineered 
tissues allows the user to control biochemical factors introduced to the tissue 
through the addition of culture medium. Many researchers are even switching 
from serum containing medium to serum-free, chemically defined medium in 
order to better assess the effects of different chemical factors. In one study 
utilizing EHT, the authors found that neonatal rat EHTs grown in serum-free 
media without any growth factor supplementation did not produce active 
contractions. Growth factors such as IGF-1, EGF, bFGF, endothelin-1, 
angiotensin II, cardiotrophin-1, and TGFB-1 were crucial for active force 
generation [Naito et al 2006]. Thus, biochemical factors play a major role in tissue 
function and may affect responses to drug compounds. 
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2.3.3.3.3 Mechanical Factors 
Mechanical stimulation is especially important when trying to model cardiac 
tissue, as cardiac cells are constantly exposed to some degree of mechanical 
loading during all stages of the cardiac cycle. Therefore any engineered tissues 
should aim to include some degree of mechanical loading. In models where cells 
self-assemble on flexible cantilevers, tissues are allowed to undergo shortening 
isotonic contractions, which corresponds with the in vivo heart [Boudou et al. 
2012]. This setup would be favorable for daily maintenance of tissues. However, 
for assessment of contractile performance, it would be ideal to have the tissue 
contract at a fixed length or adjustable lengths because resting tissue length has a 
profound effect on active force generation [Brady et al. 1991]. Early EHT models 
also incorporated cyclic strain as a source of mechanical loading [Zimmermann et 
al. 2000]. While the heart does beat cyclically, the application of cyclic strain may 
lead to lengthening contractions (tissue elongated during contraction). Such 
contractions, termed eccentric contractions, have been shown to induce cellular 
apoptosis in muscle strip models [Liaoa et al 2003]. Thus the application of cyclic 
strain to engineered tissues may not be well suited for inquiries focused on in vitro 
toxicity.  
One mechanical parameter particularly relevant to sunitinib cardiotoxicity is 
afterload. In models where tissues develop on cantilevers, the “spring constant” of 
the cantilever serves as the major determinate of afterload. The spring constant 
will be a function of the cantilever geometry and material properties. In some 
EHT experiments, the authors reinforced their silicone posts with metal braces 
during culture to make them completely rigid [Hirt et al. 2012]. They found that 
this increase in afterload increased expression of hypertrophic genes such as ANP 
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(atrial naturetic peptide) and BNP (brain naturetic peptide), increased tissues cross 
sectional area, and increased glucose consumption [Hirt et al. 2012]. The authors 
did not look into long term effects on generated force to see if force generation 
would ultimately decline in response to the chronic afterload increase. 
Additionally, making the rods completely rigid represents a non-physiologic 
increase in afterload, which hurts the relevance of their findings. Chapter 5 of this 
thesis will be aimed at examining how sunitinib’s toxicity is influenced by the 
degree of afterload. 
Along those lines, another important class of mechanical forces to consider are 
electro-mechanical forces, specifically field stimulating engineered tissues. The 
Radisic Lab has helped elucidate the role of electrical stimulation on the 
maturation of engineered cardiac tissues for the past decade. In one of their 
earliest works using neonatal rat engineered tissues, they reported that continuous 
stimulation (pulse: rectangular, 5V/cm, 2ms duration, 1Hz) led to a high degree of 
ultrastructural organization within tissues, where cardiomyocytes would align in 
the direction of electrical stimulation [Radisic et al. 2004]. In more recent work 
utilizing hPS-CMs (cardiac microwires), they report that continuous stimulation 
increased gene expression of developmental genes (myosin light chains BNP) and 
increased conduction velocities so that are within the range of healthy adult 
human hearts [Thavandirana et al. 2015]. Thus, electrical stimulation represents 
another important factor to consider incorporating into an engineered tissue 
model. 
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2.3.4 Concluding Remarks 
 Advances in human pluripotent stem cell technology and bioengineering have the 
potential for creating robust human cardiac tissue models that allow for user-control over 
cellular, biochemical, and mechanical inputs, all of which have been shown to influence 
cell function. It’s important to start considering these factors earlier on in drug 
development to create drugs that are safer and more effective. Future advances in high 
throughput screening of such tissues would make them a very attractive model system to 
adopt in pharmaceutical industry. 
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Chapter 3: Experimental Methods and Procedures 
 
3.1 Cell Culture Maintenance and Derivation 
 
3.1.1 Primary Culture of Neonatal Rat Cardiomyocytes (NRCMs) 
 NRCMs were isolated from day 0-1 Sprague Dawley rat pups. Pups were 
decapitated and a median sternotomy was immediately performed to excise hearts. Hearts 
were placed in fresh cold Hanks Balanced Salt Solution (HBSS; Gibco, Life 
Technologies, cat no 14170-112 ) with 1% Penicillin/Streptomycin/Glutamine (P/S/G; 
Gibco, cat no 10378-016), trimmed free of atria and other blood vessels, and put in fresh 
HBSS+P/S/G. Hearts were minced in a 6-well plate with ethanol-cleaned scissors and 
washed twice in fresh HBSS+P/S/G. Minced hearts were incubated with 10mL of trypsin 
(Worthington Biochemical, cat no LS003703) solution (0.1%-0.2% trypsin in 
HBSS+1%P/S/G) for 15min at 37⁰C. The resulting supernatant solution consisting of red 
blood cells and debris was removed and 10ml of fresh trypsin solution was added. 
Solution was incubated for 15 min at 37⁰C while shaking at 200 rpm. The supernatant 
was discarded again, 10ml of trypsin solution was added, and the preparation was 
incubated for an additional 15 min at 37⁰C with shaking. This time the supernatant was 
collected and filtered through a 70µm nylon mesh filter (Beckman Dickinson, cat no. 
352350) into a 50ml conical tube containing 10ml of ice cold culture media consisting of 
10% Horse Serum (Gibco, cat no 26050-088), 5% Fetal Bovine Serum (Hyclone, cat no 
SH30071.03), 10mM HEPES (Gibco, cat no 1563-0080), 1% P/S/G in 3:1 ratio of 
Dulbecco’s Modified Eagle Medium (DMEM; Gibco cat no 11965-084) and Medium 199 
(M199 1x; Gibco cat no 11043-023) on ice to stop trypsin reaction. The remaining pellet 
was subjected to additional rounds of trypsin digestion to release more cells. Released 
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cells were collected by centrifuging filtered permeate at 80xg for 5min at 4⁰C (brake off). 
Cells were plated on tissue culture plastic for 1hr at 37⁰C and 5% CO2 and supernatant 
was collected to enrich for cardiomyocytes. This CM enriched fraction was plated on 
fibronectin (Sigma Aldrich, cat no. F1141) coated dishes overnight. These cells were used 
the next day for microtissue seeding. 
3.1.2 Human Pluripotent Stem Cell Culture and Cardiac Differentiation 
 The human iPS cell line SV20 was kindly provided by iPS Core lab of Penn 
Cardiovascular Institute (http://web.expasy.org/cellosaurus/CVCL_EL23). 
Undifferentiated colonies were maintained on Matrigel ™  (Beckman Dickinson, cat no. 
35427) coated plates (0.5mg Matrigel ™  per 6 -well plate) in mTESR ™  medium (Stem 
Cell Technologies, cat no. 05850)  at 37⁰C, 5% CO2, and 21% O2. Colonies were 
passaged every 3-5 days using accutase (Sigma Aldrich, cat no A6964).  
For cardiac differentiation, iPS cells were allowed to grow for 4 days or until they 
reach ~75% confluency.  
 Day -2: Cells were dissociated with accutase and re-plated in Matrigel ™  coated 
12-well plates (2mg per 12-well plate) at a density of 106cells/well in mTeSR 
media supplemented with 5µM Rock Inhibitor (Y27632; Enzo, cat no ALX-270-
333-M005) overnight.  
 Day 0: Media was switched to RPMI 1640 (Gibco, cat no11875-085) + B27 
supplement (minus insulin; Gibco, cat no A1895601) +1µM Chiron 99021 (LC 
Laboratories, cat no. C-6556)  
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 Day 2: Media wasswitched to RPMI 1640 + B27 supplement (minus insulin) + 
2µM Wnt-C59 (Tocris Bioscience, cat no. 5148)  
 Day 4: Media was switched to RPMI+ B27 (minus insulin).  
 Day 6: Media was switched to RPMI +B27 (plus insulin; Gibco, cat no 17504-
044).   
From this point on, cells were maintained in RPMI+B27 (plus insulin) media. Initial 
beating was observed starting at day 7-12. Metabolic selection (glucose starving) was 
performed to enrich for cardiac lineages after day 10. In brief, media was exchanged to 
RPMI (without glucose; Gibco, cat no 11879-020) +5mM sodium DL-lactate (Sigma 
Aldrich cat no L4263) for 6-10 days with media changes every 2 days. Cells were given 
several days to recover after metabolic selection before performing any experiments. 
After metabolic selection, CM purity was in the range of 80-90%.  
3.1.3 Human Mesenchymal Stem Cell Culture   
Human Mesenchymal Stem Cells (hMSCs) were purchased from Lonza. hMSCs 
were maintained in alpha MEM media (Gibco, cat no 12561-056) supplemented with 
2mM (1%) Glutamax (Gibco, cat no 3505-061), and 100U/mL Penicillin / Streptomycin 
solution (P/S; Gibco, cat no. 15141-122). Cells were passaged every 3-4 days with 0.05% 
Trypsin EDTA (Gibco, cat no. 25300-054) up until passage 10 where cells became 
senescent. Cells from passages 7-10 were used for experiments involving human CMTs to 
minimize hMSC proliferation within microtissues. 
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3.2 Fabrication of µTUG Arrays  
 
3.2.1 Microfabrication of Silicon Masters 
Multilayer templates were created by photo-patterning SU-8 (all from Microchem) 
photoresist onto silicon wafers (Single-sided polished, Prime grade) using successive spin 
coats (CEE 200X, Brewer Science, Inc.), alignment (AMB 3000 HR Mask Aligner, AMB 
Inc.) and UV exposure (360nm), and baking steps. Figure 9 details this process. The base 
cantilever structure was created by spin coating SU8 2002 to create ~2.4µm layer and 
exposing this layer to 100mJ of UV (Figure 9, Step 2). To fill in the interstitial layer (the 
well), SU8 2100 was spin coated to create a ~200µm layer, followed by spin coating SU8 
2010 + 30% S1813 to create a small ~2.4µm layer, and finally, exposing a bottom layer 
photomask to 700mJ of UV (Figure 9, Steps 3-4). The top lithography was created by 
spin coating SU8 2050 to create another thin ~2.4µm layer and exposing a top layer 
photomask to 95mJ of UV (Figure 9, Steps 5-6). These masters were then developed in a 
single step in SU-8 developer (Microchem) which was stopped by submersion in 
isopropyl alcohol (IPA, Sigma cat no I9516), followed by a hard bake (Figure 3.1, Step 
7).    
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Figure 3.1: Fabrication of Silicon Masters with Soft Lithography. Templates were 
created by photo-patterning SU-8 photoresist onto wafers using successive spin coat, 
alignment and UV exposure, and baking steps. Figure Credit: Elise A. Corbin, PhD. 
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3.2.2 Fabricating µTUG arrays from Silicon Masters 
 “Stamps” (negatives of silicon wafer), were cast by pouring a pre-polymer (10:1 
base to curing agent ratio) of poly-dimethyl siloxane (PDMS, Sylgard 184; Dow Corning, 
cat no 2120925) onto wafers, degassing molds, baking overnight at 60⁰C, and peeling off 
with ethanol. These stamps could then be used multiple times to generate µTUG arrays. 
Stamps were plasma cleaned under air for 1 min on high using a Harrick expanded 
plasma cleaner (Sigma Aldrich, cat no Z561657) and silanized with trichloro -(1H, 1H, 
2H, 2H-perfluorooctyl) silane (Sigma Aldrich, cat no 448931) under vacuum overnight. 
For active force measurements, fluorescent beads (Fluoresbrite® YG Carboxylate 
Microspheres 3.00µm; Polysciences, Inc.) diluted 1:3000 in ethanol were centrifuged into 
silanized stamps to embed beads in final device. PDMS pre-polymer (5:1 to 15:1 base to 
curing agent ratio) was then poured onto silanized stamps and stamps were then inverted 
onto a hardened layer of PDMS in a 35 mm dish (Corning, cat no 430165). These 
substrates were baked at 60⁰C for 24hr. Stamps were removed from the molds carefully 
using ethanol as a lubricant to avoid damaging tops of cantilevers. Molds were washed in 
IPA and dried before seeding cells.  
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3.3 Preparation of Cardiac Microtissues  
 
3.3.1 Neonatal Rat Cardiac Microtissue Seeding Procedure 
 Neonatal rat microtissues were prepared in the same manner as described in 
Boudou et al. 2012 with a few exceptions. Figure 3.2 (panel A) gives an overview of the 
microtissue seeding process. Briefly, µTUG arrays were sterilized with 70% ethanol and 
left to dry for 30min (Figure 3.2 panel A Step 1-2). To prevent cell attachment against the 
walls of the wells, the molds were treated with 0.02% w/v Pluronic F127 (Sigma Aldrich, 
cat no P2443) for 3hr (Figure 3.2 panel A Step 3) on the surface and 30min inside the 
wells by centrifuging pluronics solution at 1600xg for 2min (Figure 3.2 panel A Step 4). 
Pluronics were washed out with Dulbecco’s Phosphate Buffered Saline solution (DPBS 
no Ca++/Mg++; Gibco cat no 14040-117) followed by dH2O (Figure 3.2 panel A Step 5). At 
this time, NRCMs were detached from tissue culture plates with 0.05% Trypsin EDTA 
for 4 min. 106- 1.2x106 NRCMs were used to seed each array. A Collagen I gel (rat tail; 
Corning, cat no. 354236) was used as an ECM in which to create microtissues. A liquid 
neutralized collagen I solution (1 mg/ml) was created by mixing collagen I, fibrinogen 
(0.5 mg/mL final concentration; Sigma Aldrich, cat no F8630), HEPES (10mM final 
conc.), NaHCO3 (4.17mM final conc.; Sigma cat no S5761), 1M NaOH (neutralization 
ratio: 0.5; Sigma, cat no S8045), M199 (10x) (1x final conc.; Sigma Aldrich, cat no. 
M0650) in sterile dH2O on ice. A base layer of collagen (1ml per array) was added and 
degassed to pull collagen into the wells (Figure 3.2 panel A Step 6). Cells were then re-
suspended into collagen solution, added to arrays, and centrifuged twice at 350xg for 90 
seconds (arrays rotated 90 degrees in between spins) (Figure 3.2 panel A Step 7-8). 
Excess collagen in between wells was removed using a vacuum aspirator (Figure 3.2 
panel A Step 9). Arrays were inverted and centrifuged at 50xg for 17 seconds to move 
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cells down the pillars. Collagen was polymerized inside an incubator at 37⁰C, 5%CO2, 
21% O2 for 15min (Figure 3.2 panel A Step 10). Culture media consisting of DMEM high 
glucose + 10% Horse Serum + 2% Chicken Embryo Extract (Charles River Laboratories, 
cat no 10100330) + 1% Antibiotic/Anti-mycotic solution (Gibco, cat no 15420-062) was 
added to arrays and arrays were put back into the incubator (Figure 3.2 panel A Step 11). 
Cells compacted ECM and tissues formed over the course of 24hr (Figure 3.2 panel B).  
 
 
Figure 3.2: Constructing Cardiac Microtissues. A) Process flow diagram for 
microtissue seeding procedure on 120 well arrays. B) Cells self-assemble and compact 
collagen matrix over 24hr to create a tissue bound to pillars. Figure adapted from: Legant 
WR, Pathak A, Yang MT, et al. “Microfabricated tissue gauges to measure and 
manipulate forces from 3D microtissues”. PNAS. 2009; 106:10097-10102; Copyright 
2009 National Academy of Sciences. 
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3.3.2 Human Cardiac Microtissue Seeding Procedure 
Human CMTs were prepared in the same manner as rat CMTs with a few 
exceptions: arrays were treated with 0.1% Pluronic F127 to allow for tissue release from 
the sides of the well. Monolayers of beating iPS-CMs (day 16-day 30) were detached 
from culture plates using TrypLE Express (Gibco, cat no 12605-010) for 7-10min at 
37⁰C/5%CO2. Human MSCs were detached from culture plates with 0.05% Trypsin 
EDTA for 5min at 37⁰C/5%CO2. iPS-CMs and hMSCs were mixed to create tissues 
composed of 93% CMs /7% hMSCs. Tissues were maintained in RPMI+ 20% 
FBS+100U/mL P/S+ 5µM Y27632 media for the first 24hr and then switched to RPMI + 
B27 (plus insulin) + 1% P/S media, which was exchanged every 2 days. Beating would 
often times not be visible during the first 2 days in culture.  
 
3.4 Drug Studies 
Stock solutions (10mM) of Sunitinib malate (LC Laboratories, cat no S-8803) 
were prepared in DMSO (Life Technologies, cat no.D12345) and were re-made every 6 
months to ensure biological activity. Stock solutions were diluted at least 1:1000 in media 
for experiments to avoid any DMSO induced toxicity. Samples treated with DMSO at the 
same %v/v were used as controls (vehicle).  Microtissues treated with 1µM Staurosporine 
(Sigma Aldrich, cat no S6942) were used as a positive control for apoptosis. Carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP; Sigma Aldrich, cat no C2759) was used a 
positive control for mitochondrial membrane potential disruption at a concentration of 
50µM and was incubated with cells for 30min. In a subset of experiments, 5-
Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, Acadesine (AICAR; Sigma 
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Aldrich, cat no A9978) was administered concurrently with sunitinib at a concentration of 
1mM. 
 
3.5 Analytical Methods  
3.5.1 Detecting Cell Death in Cardiac Microtissues 
3.5.1.1 Measuring Apoptosis via Caspase 3/7 Activation  
One of our primary metrics for assessing cardiotoxicity in CMTs is the effect of 
sunitinib on cell viability, and specifically the induction of apoptosis.  Caspase activation 
is one of the earliest signals of apoptosis in cells and involves the proteolytic cleavage of 
pro-caspase molecules into activated caspase molecules that either activate other caspases 
(initiator caspases) or are directly involved in carrying out apoptosis (executioner). 
Caspases 3 and 7 are executioner caspases expressed in nearly all tissues, and were a key 
readout for toxicity in most experiments. Because caspases are activated post-
translationally, the assay we choose must be able to selectively label the active form of 
the caspase. Additionally, because our microtissues only contain roughly 500 cells per 
tissue, we also need to utilize an assay that is sensitive enough to get a signal from only a 
few thousand cells. In light of this observation, we decided to proceed with a 
luminescence based assay as they tend to be more sensitive than calorimetric ones. 
Specifically we chose to utilize the Caspase-Glo® 3/7 assay (Promega Corporation, cat 
no PRG8090). The Caspase-Glo® assay contains a 2-part reagent consisting of 1) a cell 
lysis buffer and 2) a DEVD tetrapeptide conjugated to a luminogenic substrate. Upon cell 
lysis, activated caspases 3 and 7 will cleave the DEVD peptide, releasing the luminogenic 
substrate allowing it to react with luciferase and produce light that can be quantified 
(Figure 3.3 panel A). 
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Initial experiments with the Caspase-Glo® assay suffered from background 
issues, most likely from the serum-containing media that CMTs are cultured in. Although 
the assay is supposedly compatible with serum containing culture media, our observations 
suggested otherwise after comparing signal-to-noise ratios for samples in a) serum 
containing media, b) DPBS with residual media (~10%), or c) samples washed 
thoroughly in DPBS. The results shown in Figure 3.3 (panel B) demonstrate the 
importance of removing any residual media in order to maximize signal-to-noise ratios.  
 
 
Figure 3.3: Measuring Activated Caspase 3/7 in CMTs with Caspase-Glo®3/7.        
A) Cleavage of luminogenic substrate containing DEVD sequence by activated caspases 
induces luciferase rxn. Picture used with permission from Promega Corporation. B) 
Signal-to-noise ratios for samples treated with either 1% DMSO or 1µM sunitinib in 
various media. C) Testing the linear region of Caspase-Glo® assay using cells treated 
with 0.1% DMSO (blue line) or 1µM Staurosporine (red line); n=3 technical replicates. 
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We also took care to identify the linear operating range of this assay that was 
estimated by the manufacturer to be 50-20,000 cells. This allowed us to accurately report 
fold changes in caspase between different samples. We measured activated caspase 3/7 
levels in vehicle- and Staurosporine- (1uM; Sigma Aldrich cat no S6942) treated 2D 
cultures with cell counts of 103, 5x103, and 104 cells per well to verify that assay was 
linearly dependent in this region (Figure 3.3 panel C). This experiment confirmed that we 
can measure caspase levels using as few as 6 microtissues per experimental sample 
(roughly 1000 cell per well for 3 technical replicates). We also confirmed that that total 
protein content was did not significantly vary between experimental samples due to 
factors such as differences in tissue size (CV=0.084; n=4 independent experiments). Only 
morphologically intact CMTs were used for this and other assays, and this required 
manual selection of CMTs. 
 
3.5.1.1.1 Final Protocol for Caspase 3/7 Measurements  
Tissues were treated for 4-12hr with either DMSO or sunitinib to induce 
apoptosis. Arrays were washed with DPBS (w/o Ca++, Mg++) to remove residual media. At 
least 6 tissues (preferably 12 tissues) were collected per experimental sample and placed 
into a 1.5 mL Eppendorf tub containing ~20µl DPBS. Tissues were then re-suspended in 
366µl DPBS per tube. An equal volume (366µl) of Caspase-Glo® reagent was added per 
tube and samples were pipetted and vortexed to completely lyse tissues. 200ul of sample 
was added to a single well of a white-walled 96-well plate (Greiner bio-one, cat no. 
655083. Plates were incubated 1hr at room temperature in the dark and then analyzed on 
BioTek Synergy H1 Multi-Mode plate reader equipped with Gen5.0 software (Settings: 
quick shake, read luminescence, Gain 135, Integration Time 0.01s). 
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3.5.1.2 Trypan Blue Exclusion to Detect Late Apoptotic and Necrotic Cells  
 Measuring caspase 3/7 activation provides us insight into what is occurring during 
the early apoptotic phase. We also wish to determine whether these cells complete 
apoptosis and/or enter into a necrotic phase. Trypan Blue exclusion is a quick, cost-
effective method for identifying such cells as the dye will permeate into cells with 
damaged membranes much quicker than for cells with intact membranes, staining them 
blue, thus making them easily identified under a microscope. CMTs were treated for 
longer durations (~24hr) during this experiment to allow progression into post-apoptotic 
phase. Whole arrays or individual tissues were digested in a 1mg/mL collagenase IV 
(Gibco, cat no. 17104-019) solution in DPBS (with Ca++, Mg++) with 10% FBS for 15min 
to digest collagen I. Tissues were further broken down into single cells by dissociating 
with 0.05% Trypsin EDTA at 37⁰C with shaking at 200rpm. Cells were centrifuged at 
200xg for 5min and re-suspended in CMT culture medium at a concentration of 
approximately 5x106 cells per ml. Trypan blue exclusion was performed by mixing 0.7mL 
of media with 0.2mL of 0.4% trypan blue (Sigma Aldrich, cat no T-0776) in DPBS and 
5µl of cell suspension. The solution was incubated for 1-2 min at room temperature to 
allow for labeling of dead cells. The number of blue and white cells was counted (at least 
100 counts in total) and the percentage of dead cells was calculated using the following 
equation 1:  
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3.5.2 Characterizing Changes in Mitochondria Function and ATP Levels with Sunitinib 
Treatment 
In light of sunitinib’s effects on cellular energy sensing machinery (e.g. AMPK), 
we also desired to characterize any metabolic changes. Based on previous findings 
discussed in chapter 2, we chose to focus on changes in mitochondria and ATP levels. 
These experiments had to be performed in flat 2D cultures, as the assays we utilized were 
not adaptable to microtissue culture (see further discussion below). 
 
3.5.2.1 Measuring Changes in Cardiomyocyte Mitochondrial Membrane Potential 
Abnormalities in mitochondrial morphology have been cited in the literature, and 
there have been some preliminary experiments conducted suggesting that sunitinib can 
diminish mitochondrial membrane potential. We adapted the cardiomyocyte cell sorting 
protocol originally published by Hattori and colleagues to purify out cardiomyocytes 
based on mitochondria membrane potential via FACS [Hattori et al. 2010]. Because 
cardiomyocytes are more metabolically active than non-myocytes they express higher 
levels of mitochondria. Hattori and colleagues used a lipophilic cell permeable dye to 
selectively label the inner membrane of mitochondria, Tetramethylrhodamine, Methyl 
Ester Perchlorate (TMRM; Life Technologies, cat no T668). Because this dye labels in 
the inner mitochondria, it is also a good marker for mitochondria membrane potential, as 
it cannot enter the inner membrane without an intact membrane potential (Figure 3.4 
panel A).  
  We discovered that Hattori’s protocol suffered from limitations such as poor cell 
viability during and after cell sorting, which could confound results when a cardiotoxic 
agent such as sunitinib was being analyzed (Figure 3.4 panel C). We found that culturing 
NRCMs for 24-48hr before FACS and performing FACS in serum-free media, as TMRM 
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labeling is not compatible with lipophilic molecules such as serum, significantly 
improved viability with negligible effects on CM purity as measured by cardiac troponin I 
(cTn-I) staining (Figure 3.4 panels B-C). These improvements helped to ensure that we 
would not observe any unwanted decreases in mitochondrial membrane potential during 
analysis.  
To demonstrate that our protocol could be used to specifically analyze 
mitochondrial membrane potential, we conducted experiments with cells treated with a 
known disruptor of mitochondria membrane potential, Carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP; Sigma-Aldrich, cat no C2759). Of the three TMRM populations we 
observe on our histogram plot, we see that CCCP affects primarily the TMRM high 
population, cardiomyocytes with high levels of mitochondrial activity. We chose to 
analyze changes in this population to characterize changes in mitochondrial membrane 
potential for our studies with sunitinib.  
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Figure 3.4: Measuring Changes in Mitochondria Membrane Potential via FACS.   
A) Density dot plot of neonatal rat heart cells labeled with TMRM (580nm/30) plotted 
against autofluoresence (513nm/17). Population P3 represents TMRM high population 
consisting of CMs with abundant mitochondrial activity.  B) Post-FACS immunolabeling 
of cTnI positive cells (red) and nuclear staining (green) to identify all cells to validate 
FACS protocol.  C) Culturing neonatal rat heart cells post-isolation is critical for 
maintaining viability (red bar) post sorting and does not diminish CM purity (blue bar). 
D) Left: Characterizing changes in mitochondrial membrane potential using TMRM 
labeled cells treated with CCCP, a known disruptor of mitochondrial membrane potential. 
Right: This method can be used to identify changes in mitochondria membrane potential 
in cells treated with sunitinib.   
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3.5.2.1.1 Final Protocol Analyzing Mitochondrial Membrane Potential 
NRCMs were cultured in 24-well plates for 24-48hr post isolation before any drug 
treatments Cells were treated with 1µM sunitinib for 30min-24hr. We found that using 
concentrations in excess of 1µM lead to background interference due to sunitinib auto-
fluorescence. Cells were washed thoroughly with DPBS (no Ca++, Mg++), and labeled with 
10nM TMRM in serum free media (3:1 DMEM: M199 (1x), 10mM HEPES, 2mM 
Glutamax, 1% Insulin-Transferrin-Selenium Supplement (Gibco, cat no. 51500-056), 
100U/mL P/S) at 37⁰C and 5% CO2 for 30min. After the incubation period, cells were 
washed again with DPBS (no Ca++, Mg++) and incubated with 0.05% Trypsin EDTA for 3 
min at 37⁰C and 5% CO2. We found it critical to only treat with trypsin for <3min as any 
membrane damage will cause the TMRM to leak out. Microtissues require too much 
enzymatic digestion to obtain single cells; hence they were not used in these experiments. 
The trypsin solution was inactivated with a defined trypsin inhibitor solution (Gibco, cat 
no R007-100). Cells were collected in serum free media supplemented with 0.1% BSA 
(Sigma-Aldrich, cat no. A1470) at concentration of 2.5x106 cells/mL and filtered through 
a 70µM mesh filter. Samples were analyzed on a Beckman Dickinson LSRII Flow 
Cytometer equipped with a 488nm (blue laser for excitation and 575/26 emission filter to 
measure TMRM.  
 
Post-experimental analysis of data was performed using Flow Jo V10 software 
(FlowJo LLC). Cellular debris was filtered out using side scatter (SSC) and forward 
scatter (FSC) plots (SSC-A vs. FSC-A, Figure 3.5 panel A). Cell doublets were filtered 
out using SSC-H vs. SSC-A or SSC-A vs. SSC-W plots (Figure 3.5 panel B). The TMRM 
positive population was identified using a 575/26 histogram plot (Figure 3.5 panel C). 
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Finally, within the TMRM positive plot, the TMRM high and TMRM low populations 
were identified (Figure 3.5 panel D).   
 
Figure 3.5: Determining Changes in TMRM High Population. A) Density dot plot of 
neonatal rat heart cells SSC-A vs. FSC-A to remove cell debris from analysis. Numbers 
displayed on plot represent % cells falling within gate B) Using SSC-H vs. SSC-A dot 
plots to remove doublets from analysis.  C) Using TMRM (576/26) histogram to identify 
TMRM positive cells. D) Identifying TMRM high population within TMRM positive 
parent population.  
 
3.5.2.2 Measuring Changes in Cellular ATP levels  
 Another method we chose for characterizing the effects of sunitinib on energetics 
was to examine changes in cellular ATP levels. This assay is especially important as 
sunitinib has been shown to inhibit AMPK activity in vitro, which could lead to depletion 
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of ATP levels during times of stress, such as a hypertensive state.  Similar to our choice 
for a caspase assay, we decided to utilize a luminescence based assay that can be applied 
to a few thousand cells. We chose the ATP assay from Calbiochem (EMD Millipore, cat 
no 119107) which measures ATP levels from as few as 1000 cells. The assay utilizes 
luciferase to catalyze the formation of light from ATP and luciferin, and the light can be 
measured using a luminometer (Figure 3.6 panel A). 
 
We first identified the linear working range of the assay using purified ATP 
provided by the manufacturer. We found that we can measure as little as 1 picogram of 
ATP and stay above background and that the assay performs linearly in the range of 1-104 
picograms of ATP (Figure 3.6 panel A). However, we ran into difficulties when trying to 
perform this assay with microtissues. Even if we used tissues from the entire 140 well 
array, we couldn’t get our luminescence readings (RLU) to fall on the standard curve 
(Figure 3.6 panel B). We then switched to performing experiments in 2D, as we wouldn’t 
be limited by cell number in such experiments. We assayed ATP levels from vehicle 
(DMSO) and treated (1µM sunitinib) cells plated at densities of 105, 3x105, 6x105 cells per 
well. We found that 105 cells is sufficient to obtain luminesce readings that fell on the 
standard curve. However, with increasing cell densities, the nucleotide releasing buffer 
(i.e. lysis buffer) doesn’t seem capable of breaking down this much cellular material, as 
our readings didn’t linearly increase as we expected (Figure 3.6 panel C). Hence we 
performed all subsequent experiments in 2D at a cell density of 105 cells per well.    
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Figure 3.6: Measuring Changes in ATP Levels. A) Standard Curve obtained from using 
ATP standards to determine linear region of assay. B) Performing ATP experiments in 
CMTs does not yield sufficient signal to fall on standard curve and may not allow us to 
distinguish differences between vehicle and sunitinib treated samples.  C) Using NRCMs 
cultured in 2D flat culture at higher cell densities allow us to see changes in ATP levels 
between vehicle (1% DMSO) and treated (1µM sunitinib) cells. 
 
3.5.2.2.1 Final Protocol for Measuring ATP Levels 
Based on the considerations above, our final protocol for assaying ATP levels in 
2D NRCM cultures is as follows: NRCMs were cultured in 24-well plates and treated 
with sunitinib for 24hr. Cells were detached with 0.05% Trypsin-EDTA for 4min at 37⁰C, 
5% CO2. Cells were collected and counted and 3x105 cells per experimental sample (3 
technical replicates) were aliquoted into 1.5 mL Eppendorf tubes. Cells were centrifuged 
at 200xg for 4min to pellet cells and were re-suspended into 30µl DPBS (No Ca++/Mg++). 
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Nucleotide releasing buffer (300µl) was added to each tube to lyse cells. Samples were 
vortexed or sonicated (Bioruptor® Plus, Diagenode, Inc.) to ensure complete breakdown 
of cellular products. ATP monitoring enzyme (3µl) was added to each tube to induce 
luciferase reaction. Samples were aliquoted into a white-walled 96-well plate, taking care 
to leave at least 1 column and 1 row in between samples. ATP standards in nucleotide 
releasing buffer (1-104 picograms) were also aliquoted onto 96-well plates, and ATP 
monitoring enzyme was added to these samples as well. Plates were shaken gently for 5 
min to ensure mixing and analyzed on a BioTek Synergy H1 Multi-Mode plate reader 
equipped with Gen5.0 software (Settings: 10s shake, read luminescence, Gain 100, 
Integration Time 0.01s) (BioTek Instruments Inc.).   
 
3.5.3 Characterizing Changes in Microtissue Function following Sunitinib Treatment 
3.5.3.1 Measuring Changes in Microtissue Electrophysiology 
Our final metric for characterizing microtissue responses to sunitinib was how 
tissue functionality is affected. One critical aspect of cardiac biology is the generation of 
action potentials, which are required for systolic force generation. Cardiac microtissues 
should be able to “capture” an electrical potential and beat synchronously with the signal 
provided its frequency is within physiological range (neonatal rat 4-6Hz). Microtissue 
arrays were field stimulated by placing 2 carbon electrodes into either side of the array via 
drilling holes into the lid of a 35mm dish. Platinum wire attached to the electrodes 
connected to anode and cathode leads of stimulator (Muscle Research System, World 
Precision Instruments). Electrical stimulation parameters were: biphasic, rectangular 
pulse, 15V/cm, 1ms duration, 1ms delay, and 1Hz frequency. Microtissues were analyzed 
with respect to spontaneous beating rate (number of contractions counted within 60 sec 
interval), excitation threshold (ET, minimum stimulation voltage required for 
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synchronous contractions), and maximum capture rate (MCR, maximum beating 
frequency). These parameters were assessed starting on microtissue day 2, before and 
after treatment with sunitinib using a Nikon TE2000U inverted microscope (Nikon 
Corporation) equipped with temperature and CO2 control (37⁰C, 5% CO2). 
 
3.5.3.2 Measuring Changes in Microtissue Force Generation 
We also examined changes in force generation due to sunitinib treatment. 
Microtissues exert two types of forces: static (diastolic) and active (systolic). Static 
tension refers to forces generated in the absence of beating, and is the result of actin-
myosin cytoskeletal forces that are generated by all cells, mainly fibroblasts. These forces 
control tissue compaction and are thought to be a major contributor to overall tissue 
integrity. Static tension was inferred by measuring the displacement of the pillars. Images 
were acquired using a 10x Plan Fluor objective on a Nikon TE2000U inverted microscope 
equipped with QImaging Exi Blue camera (QImaging) and NIS BR Elements software 
(Nikon Corporation). Images were taken from the bottom, middle, and top of the micro-
wells (Figure). The width of a single cap (φ), as well as the separation between caps (S) 
and bases of pillars (B) was measured in ImageJ (NIH, imagej.net) in units of pixels 
(Figure 3.7 panel A). We derived the displacement (µm) of the pillar using the formula 
provided in equation 2, where 0.1706 is the conversion factor between pixels and microns 
for the objective used in these experiments. 
 
We then calculated the force using Hooke’s law F=kδ, where δ is the displacement 
we calculated in equation 2 and k is the spring constant of the pillar (Figure 3.7 panel B). 
The spring constant is a function of the material properties of the pillar and its geometry. 
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We directly measured the spring constants of pillars using a Hysitron TI 950 
TriboIndenter nanoindenter equipped with a Berkovich tip attached to a force transducer 
(Hysitron Inc.). The probe tip is calibrated against a hard surface to determine its elastic 
properties. The sample of interest is then loaded (PDMS array) and the probe performs a 
“scratch test” where it displaces a single cantilever on the array 14 microns in a horizontal 
direction (x-direction). The pillar is displaced four times in both the +x and –x directions. 
Based on measured forces exerted on probe from these displacements, as well as knowing 
the mechanical properties of the probe, we can directly calculate the spring constant of the 
pillar using Hooke’s law.  
 
 
Figure 3.7: Measuring Forces Generated by CMTs. A) Top: Image of the top of a 
microwell allows us to measure cap width (φ) and distance between caps (S). Bottom: 
Image of bottom well permits measurement of distance between pillar bases (B). Scale 
bar represents 100 microns in both photos. B) Calculating generated forces using 
displacement (δ) and pillar spring constants derived from material properties and pillar 
geometry.  
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For active force measurements, microtissues were electrically paced at 1Hz and 
fluorescence (435nm/20 excitation, 480nm/30 emission) video was captured (3 sec, 13 
frames per sec, gain 4, exposure time 50ms) using an Exi Blue camera and NIS Elements 
BR software to visualize active displacement of beads embedded in pillars.  Displacement 
of individual beads (in pixels) was calculated using ImageJ software. At least two beads, 
on opposite pillars, were analyzed per microtissue and averaged.   
 
3.5.4 Other Analytical Methods 
3.5.4.1 Immunocytochemistry 
To check the purity of CMs obtained post FACS, cells were labeled with the 
cardiac marker cardiac troponin-I (cTn-I, rabbit polyclonal H-170; Santa Cruz 
Biotechnology, cat no sc-15368). Briefly, cells obtained from sorting were re-suspended 
in CMT media and plated into fibronectin-coated LabTek ™ 8-well chamber slides 
(Thermo Fisher, cat no 154534) at a density of 0.3x106 cells per well and allowed to 
attach overnight. The next day, cells were fixed with 2% formaldehyde (Thermo Fisher, 
cat no\ 28906) for 15min at room temperature, followed by 3 washes with DPBS (no 
Ca++, Mg++). Samples were permeabilized with 0.01% Triton X-100 (Sigma Aldrich, cat 
no T9284) in DPBS (no Ca++, Mg++) for 10min at room temperature. To prevent non-
specific binding of secondary antibodies, samples were blocked with 5% normal goat 
serum (Cell Signaling Technology, cat no. 5425) in DPBS (no Ca++, Mg++) for 2hr at 
room temperature. A polyclonal rabbit cardiac troponin-I antibody (H-170, sc-15368; 
Santa Cruz Biotechnology) was used at 1:2000 ratio in Dako Antibody Dilutent (Agilent 
Technologies, cat no S0890) and incubated with samples overnight at 4⁰C with gentle 
shaking. Samples were then stained with goat anti-rabbit IgG (H+L) rhodamine (TRITC) 
conjugate (1:1000 in blocking solution; Jackson Immunoresearch Laboratories, cat no 
66 
 
111-025-144) for 2hr at room temperature, in the dark. To identify all cells, CMs+ non-
myocytes, samples were counterstained with 1µg/mL 4', 6-diamidino-2-phenylindole 
(DAPI; Life Technologies, cat no D21490) for 10min in the dark at room temperature to 
label nuclei. Samples were imaged using Leica TCS SP8 laser-scanning confocal 
microscope under 20X magnification.  An entire well was scanned and individual images 
were stitched together. The percentage of cTnI+ cells was determined by manually 
counting the number of double stained (TRITC and DAPI positive) and single stained 
(DAPI positive only) cells. At least 500 cells were assayed from each well on chamber 
slide. At least 2 biological replicates (2 chamber slide wells) were assayed per 
experiment.  
 
3.5.4.2 Protein Quantification 
 While optimizing Caspase-Glo® assay, we had to confirm that that total protein 
content was did not significantly vary between experimental samples. We performed 
BCA protein assays (Pierce, Thermo Fisher Scientific, cat no 23227) according to 
manufacturer’s instructions. Absorbance was measured using a SpectraMax M5 
spectrophotometer (Molecular Devices) equipped with Softmax Pro 4.8 software. 
Absorbance readings were normalized to the experimental sample with the lowest reading 
to create a linear correction factor. We found the correction factor to be unnecessary as 
CV of all protein readings across experiments was <0.0833. For ATP assay, protein 
readings were performed using Qubit® system (Thermo Fisher Scientific cat no Q33211) 
according to manufacturer’s instructions. We generated standard linear correction factors 
in the same manner as stated above and used them to normalize calculations for ATP 
(pg).  
 
67 
 
3.6 Statistical Analysis 
All graphs were plotted as mean ± standard deviation (SD); except for box-and-
whisker plots where error bars extend from median to min/max value. Individual 
experiments measuring caspase 3/7 and ATP levels were conducted on 96-well plates 
with 3 technical replicates per experimental sample. In necrosis experiments utilizing 
trypan blue exclusion, at least 70 cells were counted per measurement and both chambers 
of hemocytometer were assayed to give 2 technical replicates per experimental group. At 
least 2 experiments, utilizing different batches of NRCMs, were performed. 
Measurements of microtissue function, such as electrical and force generation, 
were assayed on individual tissues, which were treated as biological replicates rather than 
technical replicates because we found that the variability between tissues within a single 
array was far greater than the variability between different arrays. Table 3-1 compares 
coefficients of variation (CV) of individual tissues from a single array versus CV between 
at least 2 separate arrays for several functional readouts. At least 10-15 tissues were 
assayed per array for functional measurements. Additionally, due to inter-tissue 
variability, we chose to track the functional changes in individual tissues instead of doing 
a bulk average before and after treatment.  Accordingly, these data are presented as 
percent (%) change from baseline measurements conducted before treatment. 
 For experiments utilizing flow cytometry, at least 20,000 cells were analyzed per 
experimental sample, and the percentage of TMRM high cells was calculated from this 
population as described in section 3.4.2.1.1. Statistics were performed from n=3 
experimental replicates.    
 Unpaired two-tail t-tests were performed when appropriate (GraphPad 
QuickCalcs, GraphPad Software Inc.). Significance levels were determined between 
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sunitinib and vehicle treated samples and were set at *p <0.05, **p < 0.01,   ***p <0.001, 
and ****p<0.0001 or as otherwise indicated.  
 
Table 3-1 Sources of variability in measurements of microtissue function 
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Chapter 4: Creating an In Vitro Model of Human Sunitinib 
Cardiotoxicity Using the Rat Cardiac Microtissue Platform 
4.1 Rationale 
 The high prevalence of chemotherapy induced cardiotoxicity observed in patients 
can be partly attributed to a lack of preclinical models that can 1) detect early signs of 
cardiotoxicity, such as cardiomyocyte apoptosis and decreases in force generation and 2) 
identify pivotal mechanisms of sunitinib cardiotoxicity.  Identifying pivotal mechanisms 
of sunitinib cardiotoxicity using in vivo human clinical trials would not be cost effective 
and may raise ethical concerns depending on the hypothesis being tested. Current in vitro 
cell culture and animal models suffer from limitations that minimize their usefulness for 
modeling human sunitinib cardiotoxicity, such as the ability to incorporate or adequately 
control biomechanical loading conditions [Astashkina et al. 2012; Ma et al. 2016; Ogle et 
al. 2016; Zhao et al. 2016], an essential facet of cardiac biology. As such, there is a 
critical need to develop robust preclinical models that can accurately detect cardiotoxicity 
and serve as tools for enhancing our understanding of the mechanisms behind sunitinib 
cardiotoxicity. 
 Therefore, in this chapter we describe the development of an in vitro preclinical 
model of human sunitinib cardiotoxicity using a previously established cardiac 
microtissue platform. We created 3D cardiac microtissues (CMT) from neonatal rat 
cardiomyocytes that self-assemble on silicone (PDMS) cantilevers [Boudou et al. 2012]. 
We used this system to characterize sunitinib cardiotoxicity using metrics for cell 
viability (apoptosis and necrosis) and cardiac function (force generation and 
electrophysiology), and examined how these characteristics are impacted by sunitinib 
dose and treatment duration.  
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4.2 Experimental Procedures 
4.2.1 Creating rat cardiac microtissues 
 Neonatal rat cardiac myocytes were isolated as described in section 3.1.1. Cells 
were pre-plated for 1hr at 37⁰C to enrich for cardiomyocytes, and cultured overnight on 
fibronectin coated dishes. The next day, cells were washed with PBS (no Ca++ or Mg++) 
and media was exchanged to get rid of dead cells leftover from the isolation. Microtissues 
were seeded 3hr later according to methods described in section 3.3.1.  
4.2.2 Assessment of cell viability in microtissues treated with sunitinib 
Microtissues were treated with sunitinib (or DMSO vehicle) 48hr post seeding to 
allow for complete tissue compaction and induction of synchronous beating. Activated 
caspase 3/7 levels were used as a metric for apoptosis, and were measured using Caspase-
Glo® 3/7 assay described in section 3.5.1.1. Tissues were treated with drugs 4-12hr 
before assaying for apoptosis. To assess necrosis, tissues were enzymatically dissociated 
and stained with trypan blue to determine the percentage of dead cells in microtissues, 
according to methods described in section 3.5.1.2. Microtissues treated with 1µM 
staurosporine served as positive controls for apoptosis (6hr) and necrosis (24hr). 
4.2.3 Assessment of cardiac function in microtissues treated with sunitinib 
 Baseline measurements of passive and active forces were conducted prior to 
treating with sunitinib, 48hr following microtissue seeding, according to methods in 
section 3.5.3.2. Post-treatment measurements were taken after 24hr of sunitinib treatment. 
Similarly, baseline measurements of electrophysiology (spontaneous beating rate, 
excitation threshold, and maximum capture rate) were taken prior to drug treatment, 24 
and 48hr post microtissue seeding, according to methods described in 3.5.3.1.  
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Figure 4.1 Timeline for rat CMT experiments. 
 
4.3 Results 
 4.3.1 Rat CMTs recapitulate decreases in cell viability following sunitinib treatment 
 In cardiac microtissues derived from neonatal rat ventricular myocytes, we first 
examined time- and dose-dependent effects of in vitro sunitinib exposure on apoptosis as 
indicated by caspase 3/7 activation.  We employed staurosporine, a potent apoptosis 
inducer, as a positive control.  We found that a clinically relevant concentration of 
sunitinib (1µM) induced significant activation of caspases 3, 7 though to a lesser degree 
than staurosporine (Fig 4.2 panel A). Next, we evaluated how caspase activation is 
influenced by sunitinib dose and treatment duration. We found that caspase activation 
reaches a maximum level at 8 hours in CMTs treated with 1µM and 10µM sunitinib (Fig 
4.2 panel B), so all future experiments examined caspase 3/7 activation at 8 hours 
regardless of dose.  
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Figure 4.2: Detecting apoptosis in cell viability with sunitinib treatment using a rat 
cardiac microtissue model- A) Activated caspase 3/7 levels in response to treatment 
with 0.1% DMSO (Vehicle), 1µM sunitinib, or 1µM staurosporine for 8hr (DMSO and 
sunitinib) or 6hr (staurosporine); (****p<0.0001 relative to vehicle n=3 experiments; 
(*** p<0.001 1µM sunitinib vs. staurosporine n=3 experiments). B) Time dependent 
changes in caspase 3/7 activation. Fold changes (relative to vehicle) in caspase levels 
were determined for CMTs treated with 1µM or 10µM sunitinib for 4hr, 8hr, or 12hr 
[**p<0.01 1µM sunitinib 4hr vs 8hr; *p<0.05 1µM sunitinib 4hr, 8hr vs. 12hr time point; 
n=2 experiments (8hr) n=2 experiments (4hr, 12hr); ‡‡p<0.01 10µM sunitinib 4hr vs. 8hr; 
‡ p<0.05 10µM sunitinib 4hr, 8hr vs 12hr; n=2 experiments for all time points]. C) Dose 
dependent changes in caspase activation in CMTs treated with 50nM, 200nM, 1µM, 
10µM sunitinib for 8hr [*p<0.05 50nM vs. 200nM sunitinib n=2 experiments; *p<0.05 
200nM vs. 1µM sunitinib n=2 experiments (200nM) n=4 experiments (1uM); **p<0.01 
1µM, vs.10µM sunitinib n=4 experiments (1uM), n=2 (10uM) experiments]. D) Non-
linear curve fitting of panel C results yielded a log2 function (gray line), R
2=0.993.  
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When examining how caspase activation is influenced by sunitinib dose, we 
determined that 50nM is the threshold concentration for caspase activation for our model; 
and observed dose dependent increases in caspase 3/7 activation in the range 50nM to 
10µM sunitinib (Fig 4.2 panel C). Doses greater than 10µM were not deemed 
physiologically relevant to humans given observed concentrations of sunitinib in human 
blood are typically 0.1-1.89µM.  Interestingly, we found that the degree of caspase 
activation correlated strongly with sunitinib dose. Using non-linear curve fitting methods, 
we discovered that our results fit strongly with a logarithmic (log2) function that produces 
an R2 value >0.99 (Fig 4.2 panel D). Finally, we found increased numbers of late 
apoptotic/necrotic cells in CMTs treated with 10µM sunitinib as compared to vehicle 
(DMSO) treated cells after dissociating CMTs and staining with trypan blue (Fig 4.3). 
Collectively, these results demonstrate the ability of the rat microtissue model to detect 
decreases in viability due to sunitinib treatment that is dependent on sunitinib dose and 
treatment duration, and established dose and treatment duration for subsequent 
experiments.  
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Figure 4.3: Late apoptosis and necrosis in rat cardiac microtissues treated with 
sunitinib. Detecting necrotic/late apoptotic cells. CMTs were dissociated following 24hr 
treatment with 10µM sunitinib or 1µM staurosporine and the percentage of cells stained 
with trypan blue was manually measured and normalized to vehicle levels to express as a 
fold change [**p<0.01 10µM sunitinib vs. 1µM staurosporine (n=2 experiments); 
***p<0.001 vehicle vs. 10µM sunitinib n=2 experiments (sunitinib) n=3 experiments 
(vehicle)].   
 
4.3.2 CMTs reveal changes in cardiac function following sunitinib treatment 
LV dysfunction remains an important toxicity of sunitinib treatment; however 
there are a limited number of studies characterizing changes in myocyte force generation. 
Accordingly, in this part of our study, we modeled changes in microtissue force 
generation and electrophysiology using the microtissue model. We found that 1µM 
sunitinib was sufficient to decrease the spontaneous beating rates of microtissues, and 
beating rates continued to decline in a dose dependent manner (Fig 4.4 panel A), with 
complete arrest at 10µM sunitinib. Static (diastolic) forces generated by microtissues also 
decreased in a dose dependent manner (Fig 4.4 panel B). We found that active (systolic) 
force generation increased during the 24hr treatment period, which we attribute to tissues 
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maturing over time. Microtissues treated with 10µM sunitinib showed significantly 
smaller increases in force generation (Fig 4.4 panel B). When microtissues were subjected 
to field stimulation we found no significant differences in excitation threshold nor 
maximum capture rate between vehicle and sunitinib treated tissues (Fig 4.4 panel c-d). 
Results from figures 4.2-4.4 suggest that the rat cardiac microtissue model may serve as a 
robust tool for early detection of drug induced cardiotoxicity, as it can detect changes in 
cell viability and cardiac function. 
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Figure 4.4: Modeling variations in cardiac function following administration of 
sunitinib in rat CMTs- A) Dose dependent decreases in spontaneous beating rates 
following 24hr of treatment with 0.1% DMSO (vehicle n=10 tissues), 1µM sunitinib 
(n=11 tissues), or 10µM sunitinib (n=11 tissues) (**** p<0.0001 vs. vehicle; *p<0.05 
1µM sunitinib vs 10µM sunitinib). B) Dose dependent decreases in static (diastolic) 
tension generated by CMTs treated for 24hr with 0.1% DMSO (n=12 tissues), 1µM 
sunitinib (n=20 tissues), or 10µM (n=10 tissues) sunitinib (**p<0.01 vehicle vs 1µM 
sunitinib, 1µM sunitinib vs. 10µM sunitinib; ****p<0.0001 vehicle vs 10µM sunitinib). 
Decrease in active (systolic) tension with 10µM sunitinib treatment [****p<0.0001 
vehicle (n=4 tissues) or 1µM sunitinib (n=5 tissues) vs. 10µM sunitinib (n=9 tissues)]. We 
did not observe any changes in C) Excitation Threshold or D) Maximum Capture Rate 
following 24hr treatment with 0.1% DMSO or 10µM sunitinib. Data in panels A and C 
are plotted as box-and-whisker plots; Median-1st Quartile are plotted in red, 3rd Quartile-
Median are plotted in green, error bars extent from median to min/max. 
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4.4 Discussion 
 Currently, more than 100,000 people have been treated with sunitinib, and there 
are over 100 open clinical trials with this drug (clinicaltrials.org); a fact that stresses the 
notion that we need to improve our understanding of sunitinib cardiotoxicity. Many basic 
and translational studies in cardio-oncology are constrained by inadequate preclinical 
models. Animal models do not allow for precise control over biomechanical and 
biochemical factors [Houser et al. 2012]. Likewise, the use of 2-dimensional (2D) cell 
cultures for the study of sunitinib cardiotoxicity also suffers from serious shortcomings. 
Most important is the inability to incorporate essential features of cardiac physiology such 
as the application of mechanical preload and afterload [Ma et al 2016]. Taking advantage 
of recent advances in tissue engineering, we created in 3-dimensional (3D) CMTs that 
better mimic in vivo conditions without sacrificing control over cellular, biochemical, and 
mechanical inputs [Legant et al. 2008; Boudou et al. 2012]. Using the CMT platform, we 
successfully created a preclinical model for characterizing sunitinib toxicity. In the next 
chapter we will be using this model to gain insights into the mechanisms of sunitinib 
cardiotoxicity while establishing a template for broader preclinical analysis of 
cardiotoxicity for the thousands of tyrosine kinase inhibitors currently in development. 
 
 We first confirmed that our microtissue model could recapitulate previously 
observed increases in cell death with sunitinib treatment. Our model was able to detect 
significant increases in caspase 3/7 activation following treatment of physiological doses 
of sunitinib, which is consistent with reports by Hassinoff et al. and Dohertry et al. 
[Hassinoff et al. 2008; Doherty et al. 2013]. We are the first to report that the degree of 
caspase 3/7 activation correlates logarithmically (log2) with sunitinib dose. Additionally 
we found that caspase activation was time dependent, a finding that also observed by 
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Hassinoff and colleagues [Hassinoff et al. 2008]. Our results also demonstrated that many 
of these early apoptotic cells go on to become non-viable, leading to cardiomyocyte loss, 
which is consistent with studies reporting elevated troponin levels in patients [Chu et al. 
2007], CK-MB elevations in rodent studies [Maayah et al. 2014], and increases in 
TUNEL positive cells in in vitro NVRM studies [Chu et al. 2007]. In summary, our 
microtissue model detects activation of apoptosis pathways and cell death with sunitinib 
treatment and our results are in-line with existing studies in the literature, while still 
providing some novel findings regarding the relationship between sunitinib dose and 
activation of apoptosis.  
   Our microtissue model detected dose dependent decreases in spontaneous beating 
rate and full cardiac arrest at 10µM sunitinib, which is consistent with findings by 
Doherty and colleagues [Doherty et al. 2013]. These dose-dependent decreases in beating 
may have been connected to findings that sunitinib blocks hERG channels at 
physiological doses (see section 2.1.2.1 for more details). Neonatal rodent cells do 
possess a small hERG current and blocking it has been shown to lead to arrhythmias [Lin 
et al. 2010; Gilchrist et al. 2015]. Because we did not measure action potential waveforms 
in this experiment, we cannot be certain that our findings are due to hERG channel 
blockage. Interestingly, we found no difference in electrophysiology parameters such as 
excitation threshold and maximum capture rate, both of which are measured under field 
stimulation. These results suggest that in the presence of an outside current, sunitinib’s 
effects on electrophysiology are limited.  Furthermore, sunitinib has been primarily 
shown to induce atrial fibrillation, and CMTs we created are primarily of ventricular 
phenotype [Tamargo et al. 2015], so that may explain why we didn’t observe more 
dramatic effects on some electrophysiology parameters.  
In addition to changes in electrophysiology, we also observed dose dependent 
decreases in static (diastolic) tension generated by microtissues. Static tension is a 
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measure of forces exerted by tissue at rest and would be influenced by cardiomyocyte 
loss. We cannot ascertain whether myocyte loss is solely responsible for observed 
decreases or if other mechanisms contribute to reduced force generation. Our findings for 
tension partially differ from those of Rainer and colleagues who reported decreases in 
systolic but not diastolic stresses in short term (30min) sunitinib experiments (doses 
≥1.87µM) performed on human atrial muscle strips, but many differences in experimental 
preparation may have contributed to the differences observed [Rainer et al. 2012]. 
 
4.5 Limitations and Conclusions 
4.5.1 Study Limitations  
One limitation in this study is the use of neonatal rat cells to model adult human 
cardiotoxicity. In the absence of an adult human cardiomyocyte cell line, NRCMs have 
been utilized for years and are able to recapitulate many aspects of human cardiac biology 
Nevertheless, there are valid concerns about potential inter-species differences. Though 
cardiac myocytes derived from human pluripotent derived cardiac stem cells mitigate the 
species difference, these cells are functionally immature. Another limitation in our work 
is the inability to distinguish between dead cells and “sick” cells in our functional data. 
We cannot discern whether cells are becoming “sick” due to sunitinib and can’t generate 
as much force per cell, or whether there are fewer live cells contributing to force 
generation. However, our results demonstrating that sunitinib decreases spontaneous 
beating rate may give us some insight into this issue. In the case of spontaneous beating 
rate, we are only looking at the function of live cells, as the dead cells cannot beat. Our 
results clearly demonstrate a decrease in the beating rates of live cells in CMTs treated 
with sunitinib. This result suggests that sunitinib is making cells “sick” and less 
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functional.  Hence it may be possible that sunitinib is impacting myocyte force generation 
independent of myocyte attrition due to apoptosis. Another limitation with the microtissue 
model is the inability measure systolic tension at a fixed tissue length. Because of the 
decrease in diastolic tension we were concerned that sarcomere lengths were also 
changed, which in itself would affect systolic tension due to the Frank-Starling 
relationship [Brady et al. 1991]. Therefore, the effects of sunitinib on active force 
generation can be confounded by any changes in static tension. For example, if sunitinib 
causes decreases in static tension that lead to increases in sarcomere length, that 
sarcomere change alone will tend to increase active force generation. If sunitinib is 
actually directly decreasing active force generation, we may not be able to observe this 
decrease because of the increase in sarcomere length favoring increased active force 
generation. Ideally, to separate out length-dependent changes of active tension, these 
measurements must be performed on tissues of a fixed length. We currently do not have 
to capability to manipulate microtissues in this manner. 
 
4.5.2 Conclusions 
As tyrosine kinase inhibitors such as sunitinib continue to be widely used in the 
treatment of cancer, better preclinical models for identifying the risks and mechanisms of 
cardiotoxicity will be very important. We have created an in vitro model of sunitinib 
cardiotoxicity that allows us to identify effects on cell viability and cardiac function. We 
were able to recapitulate decreases in myocyte viability and function that were described 
in previous studies and we were the first group to fully characterize the effects of 
sunitinib dose and duration on cardiomyocyte loss and function. The model described in 
this study may also serve as robust tools for disease modeling.  
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Chapter 5: Identifying Pivotal Mechanisms of Sunitinib 
Cardiotoxicity: Contributions of Afterload and Mitochondria 
Dysfunction 
 
5.1 Rationale 
 In humans, sunitinib causes increases in blood pressure, and induces hypertension 
in up to 47% of treated individuals [Bono et al. 2011; Demetri et al. 2006; Di Lorenzo et 
al. 2011]. A small cohort of these patients goes on to develop LV dysfunction (<10%) 
[Shah RR et al 2015; Telli et al. 2008; Hall et al. 2013].  However, the direct interaction 
between load and cardiac dysfunction in the setting of sunitinib remains completely 
unknown.  Hypertension induces the heart to generate greater forces, and it is well 
documented that increased afterload is risk factor for eventual LV dysfunction [Ozkan et 
al. 2011; Fernandes-Silva et al. 2016]. The question of whether the development of 
hypertension merely coincides with sunitinib toxicity or if increased afterload directly 
potentiates the risk of cardiac toxicity for any specific dose/duration has important 
clinical relevance. We hypothesized that increased afterload will augment the cardiotoxic 
effects of sunitinib. 
In addition to afterload, mitochondrial dysfunction is thought to be another 
mechanism for sunitinib cardiotoxicity. Endomyocardial biopsies from patients being 
treated with sunitinib have revealed swollen mitochondria, and in vitro studies with 
sunitinib have revealed qualitative changes in mitochondrial membrane potential [Chu et 
al. 2007; Kerkela et al. 2009]. However, mitochondria dysfunction as it relates to 
sunitinib has not been fully characterized.  
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Therefore, in this chapter we assessed the contributions of afterload and 
mitochondria dysfunction in the context of sunitinib cardiotoxicity. We were able to 
create cantilevers with different stiffnesses to vary the amount of afterload experienced by 
microtissues. We used apoptosis, via caspase 3/7 activation, as a metric for characterizing 
the cardiotoxic effects of afterload. In the second part of this chapter, we quantitatively 
characterized mitochondria dysfunction with sunitinib treatment using our own advances 
in mitochondria labeling and flow cytometry. We evaluated mitochondrial function 
changes with sunitinib treatment duration. We then looked at the impact of mitochondrial 
dysfunction on cell energetics by measuring cellular ATP levels. Finally, we evaluated 
whether upstream activation of AMPK, using molecule AICAR, could rescue sunitinib 
induced caspase 3/7 activation.   
 
5.2 Experimental Methods 
5.2.1 Characterizing mitochondrial dysfunction  
 In these experiments, NRCMs were cultured in flat culture in 24-well plates for 
48hr post isolation. Cells were treated with 1µM sunitinib for 30min-24hr and 
subsequently labeled with TMRM to identify quantitative changes in mitochondria 
membrane potential as described in section 3.4.2.1.1. Cells treated with 50µM CCCP 
were used as a positive control for membrane potential disruption in these experiments. 
ATP levels were measured after 24hr treatment with sunitinib as described in section 
3.5.2.2.1.  We also explored the ability of the AMPK activator AICAR to reduce sunitinib 
induced caspase activity as described in section 4.2.2. 
83 
 
5.2.2 Creating microtissues under varying degrees of afterload 
 Devices were fabricated using either a 5:1 or 15:1 base-to-curing ratio to create 
arrays with stiff or soft pillars respectively. The resulting spring constants from these 
pillar configurations were 1.16157±0.09821 N/m (28 pillars tested) for stiff pillars and 
0.55982±0.17612 N/m for soft pillars (20 pillars tested), as measured by nanoindentation 
as described in section 3.5.3.2. Rat cardiac microtissues were seeded in the same manner 
as described in section 4.2.1. 
5.2.3 Assessing the Contribution of Afterload 
 We chose to characterize the effect of afterload on sunitinib cardiotoxicity in 
terms of apoptosis, specifically caspase 3/7 activation. Activated caspase 3/7 was 
measured using Caspase-Glo® 3/7 assay as described in sections 3.5.1.1 and 4.2.2.  
 
5.3 Results 
5.3.1 Sunitinib induces decreases in mitochondrial membrane potential and cellular ATP 
levels 
Recognizing that mitochondrial dysfunction is a proposed mechanism of sunitinib 
cardiotoxicity, we assayed mitochondrial membrane potential in NVRMs at various time 
points following treatment with 1µM sunitinib using TMRM and a flow cytometric 
analysis. When mitochondria membrane potential is impaired, TMRM will not be able to 
label the inner membrane of mitochondria. We used (CCCP), a known disruptor of 
mitochondrial membrane potential, as a positive control for these experiments. Figure 5.1 
(panel A) shows a typical histogram of TMRM levels in vehicle, sunitinib (1µM), and 
CCCP (50µM) treated NVRMs. The plot demonstrates modest decreases in mitochondrial 
membrane potential with 1uM sunitinib treatment; albeit this decrease is not as significant 
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as one observed with CCCP treated cells. We hypothesized that like caspase activation, 
mitochondrial membrane potential may also exhibit time dependent changes, therefore we 
quantified differences in mitochondrial membrane potential between vehicle and sunitinib 
treated cells across various time points (Fig 5.1 panel B). We found significant decreases 
in mitochondria membrane potential at 4 hour and 8 hour treatment durations, but none 
before or after this time interval. Interestingly, these time points also correspond to when 
we observed caspase 3/7 activation. We also observed modest decreases in cellular ATP 
levels in NVRMs treated with 1uM sunitinib for 24hr (Fig 5.1 panel C).  
Previous studies have identified the inhibition of AMPK activity as an off target 
effect of sunitinib, which is another possible explanation for decreased ATP levels. We 
hypothesized that treating CMTs with an AMPK activator, AICAR, could reverse some 
of the observed cardiotoxic effects of sunitinib, specifically caspase 3/7 activation. 
However, upstream activation of AMPK with AICAR was not sufficient to attenuate 
caspase 3/7 activation in sunitinib treated cells (Fig 5.1 panel D). Our results reveal time 
dependent changes in mitochondrial membrane potential with sunitinib treatment, which 
may contribute to observed decreases in cellular ATP levels. 
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Figure 5.1: Characterizing changes in mitochondrial function and cell energetics 
with sunitinib treatment– A) Flow cytometry histogram showing levels of TMRM, a 
dye used to measure mitochondrial membrane potential. NVRMs grown in flat culture 
were treated with 0.1% DMSO (vehicle), 1µM sunitinib, or 50µM CCCP (known 
disruptor of mitochondria membrane potential) for 30min (CCCP) or 4hr (DMSO and 
sunitinib) and then were labeled with 10nM TMRM. B) Time dependent decreases in 
mitochondria membrane potential following treatment with 1uM sunitinib. NVRMs 
grown in flat culture were treated with 0.1% DMSO or 1µM Sunitinib for 30min-24hr and 
labeled with TMRM to assess mitochondria membrane potential (*p<0.05 n=3 
experiments). C) Decreases in ATP levels in NVRMs following 24hr treatment with 1µM 
sunitinib (*p<0.05 n=3 experiments). D) Upstream activation of AMPK with molecule 
AICAR did not reverse sunitinib induced caspase activation in rat CMTs (n=2 
experiments). 
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5.3.2 Cardiotoxic effects of sunitinib are augmented by increased afterload in CMT model 
Though hypertension frequently accompanies sunitinib treatment and most 
patients with sunitinib-induced cardiotoxicity have hypertension, it remains unclear 
whether hypertension is a marker or a mediator of cardiac dysfunction. Recognizing that 
the stiffness of the cantilever is the primary load constraining active shortening of the 
tissue (i.e. afterload), we cultured CMTs for 48hr on stiff (5:1 base-to-curing ratio) and 
soft (15:1 base-to curing-ratio) pillars and treated them with either 0.1% DMSO (vehicle) 
or 1µM sunitinib for 8 hours. Figure 5.2 (panel A) shows caspase 3/7 activation for this 
experiment. In vehicle treated CMTs, we see greater caspase activation in soft pillars 
versus stiff pillars. However, in sunitinib treated tissues, we observed greater caspase 
activation in stiff versus soft pillars. When this data is graphed as a fold change (Fig 5.2 
panel B), we see that increased afterload augments sunitinib-induced caspase 3/7 
activation. These results suggest that increased afterload augments the myocardial toxicity 
associated with a given dose and duration of sunitinib. 
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Figure 5.2: Using CMTs to assess the contribution of afterload to observed 
cardiotoxic effects of sunitinib- A) rat CMTs cultured on stiff (5:1) or soft (15:1) pillars 
were treated with 0.1% DMSO (vehicle) or 1µM sunitinib for 8hr. Differences in active 
caspase 3/7 levels were observed between soft and stiff vehicle treated CMTs (** p<0.01; 
n=3 experiments) and sunitinib treated CMTs (*** p<0.001; n=3 experiments). B) 
Results in part A) plotted as fold changes in active caspases 3/7 relative to vehicle treated 
CMTs (**p<0.01 n=3 experiments).   
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5.4 Discussion 
In addition to creating a preclinical model for sunitinib we also wanted to gain 
mechanistic insights to sunitinib cardiotoxicity. Our findings of modest, yet significant, 
decreases in mitochondrial membrane potential with sunitinib treatment complements 
patient biopsies showing swollen mitochondria and in vitro studies showing qualitative 
decreases in mitochondrial membrane potential at a single time point [Kerkela et al. 2009; 
Chu et al. 2007; French et al. 2010]. To our knowledge, we are the first group to define 
the time-dependence of changes in mitochondrial membrane potential following sunitinib. 
Interestingly, decreases in mitochondrial membrane potential corresponded to same time 
points when we observed caspase activation. It has been previously shown that activated 
caspases 3 and 7 are key mediators of mitochondrial apoptosis events, such as decreases 
in membrane potential [French et al. 2010; Lakanhi et al. 2006; Safiulina et al. 2006]. 
Mitochondrial swelling has been shown to accompany loss in membrane potential. Future 
work would need to done to separate out the direct effects of sunitinib on mitochondrial 
function vs. indirect effects on mitochondria due to sunitinib-induced apoptosis. One 
experiment that may be useful to distinguish these two mechanisms would be to treat 
NRCMs with a caspase 3/7 inhibitor prior to administration of sunitinib. If mitochondria 
function is still impaired in the absence of caspase activation, then sunitinib is more likely 
to be directly impacting mitochondrial function, as opposed to indirectly via caspase 3/7 
activation. 
We further observed modest decreases in ATP levels, similar to those reported by 
Kerkela and colleagues [Kerkela et al. 2009], and these may be consequent to the changes 
in mitochondrial membrane integrity. Another possible explanation for decreases in ATP 
levels is AMPK inhibition by sunitinib (IC50=0.062±0.029µM for rat [Laderoute et al. 
2010]). Cohen and colleagues reported that sunitinib cardiotoxicity could be rescued by 
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the addition of an upstream AMPK activator, AICAR [Cohen et al. 2011]. In our 
experiments with AICAR treatment, we found no significant change in caspase 3/7 
activation. Interestingly our results appear to support findings by Kerkela and colleagues 
[Kerkela et al. 2009], who report that sunitinib affects intrinsic kinase activity. Perhaps 
upstream activation of AMPK by AICAR is not properly targeting the mode of sunitinib’s 
inhibition of AMPK, and a different AMPK activator should instead be used. In 
summary, our characterization of mitochondrial dysfunction in NRCMs ties together our 
caspase results from microtissues as well as previous findings of swollen mitochondria 
and decreased ATP levels.  
The CMT model is particularly well-suited for examining whether increases in 
afterload augment cardiotoxic effects of sunitinib. We varied afterload by altering the 
stiffness of the pillars on which CMTs are tethered. We observed an increased magnitude 
of sunitinib-associated caspase activation with pillars. When CMTs are cultured on stiff 
pillars in the absence of sunitinib, we actually observed somewhat lower caspase 
activation, further supporting an interaction between sunitinib and increased afterload. 
More specifically, the switch in increased apoptosis from soft to stiff pillars following 
sunitinib treatment suggests that sunitinib may be impairing normal adaptive responses to 
increased afterload. Increased mechanical forces, such as afterload, have been shown to 
promote the formation and maturation of focal adhesions, which are adhesions between 
cellular integrins and ECM molecules. Tyrosine kinases, Src and focal adhesion kinases 
(FAK) are recruited to these focal adhesions and are activated via phosphorylation. 
Activated Src and FAK can inhibit apoptosis via MAPK/ERK pathway [Aikawa et al. 
1997]. This could explain why we saw lower caspase activation on stiff pillars:  the 
increased afterload may have resulted in greater levels of activated Src and FAK 
[Franchini et al. 2000]. It appears that sunitinib can inhibit these tyrosine kinases, though 
to a lesser degree than its effects on RTKs. For example, in a model of glioblastoma, 
90 
 
treatment with 10µM sunitinib led to decreased levels of activated FAK and Src [de 
Boürd et al. 2007]. Perhaps inhibition of the anti-apoptotic effects of Src and FAK by 
sunitinib can explain why we observed greater caspase activation on stiff pillars following 
sunitinib treatment even though caspase levels on stiff pillars was in fact lower in vehicle 
treated groups.     
Our results are in line with previous rodent studies that found that concurrent 
administration of a vasopressor (phenylephrine) was required to observe LV dysfunction 
with sunitinib [Doherty et al. 2013; Khakoo et al. 2008], which suggest that afterload is a 
key mediator of sunitinib’s effects on LV function. It is tempting to speculate that the 
energetic stress caused by decreased in ATP generation (due to sunitinib) combined with 
an increased bioenergetics demand induced by increased afterload reach the threshold for 
inducing caspase activation. Even in the absence of definitive proof for this speculation, 
our findings support a more aggressive treatment of hypertension in patients treated with 
sunitinib to prevent (or limit) LV dysfunction. 
 
5.5 Limitations and Conclusions 
5.5.1 Study Limitations 
One major limitation in the study was the inability to conduct experiments relating 
to mitochondrial membrane potential and ATP measurements with CMTs. Flow 
cytometry required a single cell suspension and digesting microtissues enzymatically 
resulted in TMRM dye leaking out. ATP measurements required an abundance of cells 
that we could not obtain with CMTs. Additionally, in these experiments, we found that 
dosing cells with concentrations >1µM sunitinib resulted in significant background 
fluorescence. Hence we only conducted these experiments at the 1µM sunitinib level. 
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Fortunately, this is a clinically relevant concentration of sunitinib. Finally, with regard to 
our experiments with afterload, we realize our study would hold more clinical relevance if 
we could induce changes in afterload after CMT formation instead of creating CMTs on 
different in the presence of different pillar stiffness, because secondary changes in 
cantilever stiffness would better mimic the secondary development of hypertension after 
sunitinib exposure. The ability to induce secondary changes in afterload is an active area 
of investigation in our research group.     
 
5.5.2 Conclusions 
Many studies cite an association between developing hypertension and the 
eventual development of LV dysfunction during or after sunitinib treatment. The 
contribution of increased afterload to sunitinib’s cardiotoxic effects has been 
understudied.  Though it is possible that higher afterload in vivo simply unmasks LV 
dysfunction induced by sunitinib, our findings support the concept that increased 
afterload actually augments cardiotoxicity of sunitinib. Our results suggest that 
management of hypertension may be important for preventing eventual LV dysfunction in 
patients receiving sunitinib.  Additionally, we are the first group to fully characterize loss 
of mitochondrial membrane potential with sunitinib treatment, and relate the temporal 
pattern of these changes to the timing of caspase activation following sunitinib exposure.  
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Chapter 6: Analyzing Responses of Human Cardiac 
Microtissues to Sunitinib 
6.1 Rationale 
 Although neonatal rat cardiomyocytes do recapitulate most of the essential 
features of cardiac physiology, the clinical relevance our rat cardiac microtissue model 
may ultimately be limited by inter-species differences between rodents and humans 
[Houser et al. 2012]. In the absence of a human cardiomyocyte cell line, researchers have 
begun creating sources of human cardiomyocytes by differentiating pluripotent stem cells. 
As section 2.3.2 discussed, these pluripotent derived cardiomyocytes are immature (fetal-
like) and do not recapitulate many features of adult cardiac biology [Yang et al. 2014]. 
Nevertheless, these cells are currently being utilized to study responses to 
pharmacological agents, and their ability to be incorporated into 3-dimensional constructs 
tends to help them mature compared with 2-dimensional culture conditions [Burridge et 
al. 2016; Broekel et al. 2016; Fong AH et al. 2016]. For this reason, we felt that it was 
important to start transitioning our cardiac microtissue model to include studies with 
CMTs composed of human cardiac cell sources. 
 Therefore, in this chapter we examined the responses of human CMTs to sunitinib 
using caspase 3/7 activation as our primary metric for cardiotoxicity. We compared 
sensitivity of human and neonatal rat CMTs. Finally, we assessed how caspase activation 
in response to sunitinib is impacted by afterload in human CMTs. 
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6.2 Experimental Methods 
6.2.1 Creating human cardiac microtissues 
 Human cardiomyocytes were derived from pluripotent stem cells according to the 
differentiation protocol described in section 3.1.2. These cardiomyocytes were mixed 
with human mesenchymal stem cells (MSCs) to create tissues that were 93% CM / 7% 
MSCs. Microtissues were seeded according to methods described in section 3.3.2. 
Microtissues were treated with sunitinib on day 5 of microtissue culture.   
6.2.2 Assessing the Contribution of Afterload 
 Devices were fabricated using either a 5:1 or 15:1 base-to-curing ratio to create 
arrays with stiff or soft pillars respectively, as described in section 5.2.1. We chose to 
characterize the effect of afterload on sunitinib cardiotoxicity in terms of apoptosis, 
specifically caspase 3/7 activation. Activated caspase 3/7 was measured using Caspase-
Glo® 3/7 assay as described in sections 3.5.1.1 and 4.2.2.  
 
6.3 Results 
6.3.1 CMTs composed of human pluripotent stem cell derived cardiomyocytes exhibit 
afterload dependent capsase 3/7 activation following sunitinib treatment 
To extend these observations, we created CMTs composed of human iPS derived 
cardiomyocytes mixed with human mesenchymal stem cells (huMSCs) and examined 
their responses to sunitinib. Human CMTs treated with 1µM and 10µM sunitinib for 8hr 
exhibited significant elevations in caspase 3/7 levels (Fig 6.1 panel A). When we 
compared these responses to ones we obtained with rat CMTs treated at same 
concentration of sunitinib, we found that human CMTs have nearly 3-fold greater caspase 
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activation than rat CMTs at the 10µM dose. When human CMTs are treated with a more 
physiologically relevant dose of sunitinib (1µM), we found that caspase activation is very 
similar to what we observed in rat CMTs (Fig 6.1 panel A). These results suggest that 
human CMTs exhibit robust responses to sunitinib treatment. 
Next we sought to address our hypothesis that increased afterload augments 
sunitinib cardiotoxicity in human CMTs. Human CMTs were cultured on stiff (5:1 
PDMS) or soft pillars (15:1) for 5 days before being treated with 1µM sunitinib for 8 
hours. We found that human CMTs cultured on stiff pillars exhibited a nearly 3-fold 
increase in caspase 3/7 activation following sunitinib treatment compared to human 
CMTs cultured on soft pillars (Fig 6.1 panel B). In fact, caspase 3/7 levels were 
minimally increased (1.15±0.078 fold change) following sunitinib treatment in human 
CMTs cultured on soft pillars. This finding varies from what we observed in rat CMTs, 
where caspase 3/7 levels did increase following sunitinib treatment (1.74±0.064 fold 
change). In summary, increase afterload augments sunitinib induced caspase 3/7 
activation in human CMTs. 
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Figure 6.1: Sunitinib cardiotoxicity in CMTs composed of human pluripotent 
derived cardiomyocytes (iPS-CMs) - Differentiation day 20-30 iPS-CMs derived from 
SV20 iPS cell line were combined with 7% huMSCs to create human CMTs. A) Fold 
changes in activated caspase 3/7 levels of human CMTs on stiff pillars treated 8hr with 
0.1% DMSO (vehicle) or 1µM, 10µM sunitinib for 8 hours compared to neonatal rat 
CMTs [**p=0.0116 10µM sunitinib human CMTs (n=2 experiments) vs. neonatal rat 
CMTs (n=2 experiments)]. B) Human CMTs were cultured on stiff (5:1) or soft pillars 
(15:1) and treated with 1µM sunitinib for 8hr. Plotted are fold changes (relative to 
vehicle) in caspase 3/7 levels in human and rat CMTs [**p<0.01 human CMTs on stiff vs. 
soft pillars (n=2 experiments); **p<0.001 human CMTs (n=2 experiments) vs. neonatal 
rat CMTs (n=3 experiments) cultured on soft pillars]. 
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6.4 Discussion 
The final part of our study was aimed at examining responses of human 
pluripotent derived cardiomyocytes to sunitinib. We found the human CMTs exhibited 
significant activation of caspase 3/7 in response to 10µM sunitinib, more than 3 times 
what we observed in rat CMTs (Fig 6.1 panel A). It’s possible that this difference is 
species-related or maturation-related. Such differences could impact sensitivity to 
cardiotoxic agents like sunitinib. Our results are in stark contrast to other studies utilizing 
iPS-CMs that required much higher concentrations of sunitinib to see decreases in cell 
viability (caspase activation and/or LDH release) in 2D cultures. For example, Cohen and 
colleagues had to dose flat cultures of iPS-CMs with 23µM sunitinib to get a 2 fold 
activation of caspase 3/7, which is well outside physiological range of sunitinib 
concentrations observed in vivo, making their results less clinically relevant (Cohen et al. 
2011). The human CMT model, on the other hand, displayed more than a 2-fold increase 
in caspase 3/7 activation with just 1µM sunitinib (on stiff pillars). These differences may 
be due to differences in iPS-CM derivation and/or choice of culture platform (2D vs. 3D), 
but it is tempting to speculate that the biomechanical loading intrinsic to the CMT model 
(and clinical sunitinib use) is an important regulator of sunitinib cardiac toxicity. Such 
speculation is further supported by our finding that increased afterload not only augments, 
but is required for sunitinib induced caspase 3/7 activation in human CMTs (Fig 6.1 panel 
B). The dependence of cardiotoxicity on afterload correlates well to clinical findings that 
hypertension is associated with the eventual development of LV dysfunction. Our results 
suggest that human CMTs with capacity for adjusting in vitro afterload represent an 
important advance for modeling human sunitinib cardiotoxicity.  
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6.5 Limitations and Conclusions 
One major limitation associated with pluripotent derived cardiomyocytes is that 
they are fetal-like in nature and do not exhibit all of the hallmarks of adult cardiomyocyte 
physiology. Therefore their responses to pharmacological agents may differ from the 
response of an in vivo adult heart. Nevertheless, we believe that iPS-CMs are suitable to 
use in experiments primarily focused on examining effects of sunitinib on cell viability. 
Additionally, in our experiments examining the contribution of afterload to sunitinib 
toxicity, we would preferentially perform these experiments using secondary changes in 
afterload, as we discussed earlier in section 5.4. Proposed methods for inducing secondary 
afterload changes in CMTs will be discussed in the next chapter. Despite these 
limitations, our finding that human CMTs experience afterload dependent caspase 
activation in response to sunitinib supports clinical findings that hypertension, in many 
cases, is a predictor of future LV dysfunction. The fact that our CMT model recapitulates 
this finding makes it a useful tool for studying sunitinib induced cardiotoxicity.   
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Chapter 7:  Conclusions and Future Work 
7.1 Summary of work 
Cardiotoxicity remains an important detrimental clinical consequence of 
chemotherapy treatment.  Sunitinib, a multi-targeted oral tyrosine kinase inhibitor used to 
treat renal cell carcinoma and gastrointestinal stromal tumors, is associated with 
hypertension in up to 43% of patients and left ventricular dysfunction in up to 9.7% of 
patients. Current preclinical models, such as animal models and in vitro cell culture 
models are not well-equipped for identifying and characterizing pivotal mechanisms of 
sunitinib induced cardiotoxicity. Thus, our current understanding of sunitinib 
cardiotoxicity is limited; in particular our understanding of the role of alterations in 
mechanical loading and mitochondrial function is very limited. This dissertation centered 
on: 1) Creating a preclinical model of human sunitinib cardiotoxicity using engineered 
tissues; and 2) Elucidating the roles of mitochondrial dysfunction and increased 
mechanical loading in the context of sunitinib cardiotoxicity. 
7.1.1 Creating a preclinical model of human sunitinib cardiotoxicity using engineered 
tissues 
 In Chapter 4 we described the development of an in vitro preclinical model of 
human sunitinib cardiotoxicity using a previously established cardiac microtissue 
platform where 3D cardiac microtissues (CMT) could be formed from neonatal rat 
cardiomyocytes. We used this system to characterize sunitinib cardiotoxicity using 
metrics for cell viability (apoptosis and necrosis) and cardiac function (force generation 
and electrophysiology), and examined how these characteristics are impacted by sunitinib 
dose and treatment duration. 
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 We found that as little as 50nM sunitinib was sufficient to induce caspase 3/7 
activation (1.43 ±0.10 fold increase over vehicle), which is well within the range of 
sunitinib concentrations found in human blood plasma [Faivre et al. 2005]. The degree of 
caspase 3/7 activation scaled to sunitinib dose logarithmically (log2; R
2>0.99). Caspase 
3/7 levels were found to peak at 8hr following treatment. We also detected increases in 
the proportions of necrotic cells in microtissues treated with sunitinib (1.84±0.11 fold 
higher than vehicle). These results suggested that our microtissue model was suitable for 
detecting early changes in cardiomyocyte viability with sunitinib treatment.   
 Next we sought to assess changes in CMT function with sunitinib treatment. We 
observed dose dependent decreases in diastolic and systolic tension with sunitinib 
treatment. We could not discern whether observed decreases in systolic tension were due 
to changes in resting sarcomere length, which is unlikely given the decreases in diastolic 
tension we observed. Decreases in diastolic tension would tend to favor increases in tissue 
(and sarcomere) length which by the Frank Starling principle would cause active tension 
to increase. We also observed dose-dependent decreases in the spontaneous beating 
frequency of microtissues treated with sunitinib. However, when microtissues were 
subjected to field stimulation, we found no difference in electrophysiology parameters 
such as excitation threshold and maximum capture rate. A major limitation we cited in 
this group of experiments was the ability to distinguish whether the observed changes in 
function are directly or indirectly due to sunitinib treatment. Specifically, is sunitinib 
directly impacting force generation and beating frequency; or is the injury to myocytes 
and apoptosis responsible for the decreases in function we observed? This is an important 
consideration for all research groups utilizing multi-cellular preparations to assess drug 
toxicity and its impacts on function. Nevertheless, the cardiac microtissue model appears 
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to recapitulate many of the observed cardiotoxic effects of sunitinib cited in the literature 
and clinic.  
7.1.2 Elucidating the roles of mitochondrial dysfunction and increased mechanical 
loading  
The direct interaction between load and cardiotoxicity in the setting of sunitinib 
has been uncertain. We hypothesized increased afterload will augment the cardiotoxic 
effects of sunitinib. In addition to afterload, mitochondria dysfunction is thought to be 
another mechanism for sunitinib cardiotoxicity given the evidence of mitochondria 
swelling from patient biopsies [Chu et al. 2007]. However, mitochondria dysfunction as it 
relates to sunitinib has not been fully characterized.  
Chapter 5 began with characterizing changes in mitochondrial dynamics with 
sunitinib treatment. Experiments with TMRM, an indicator of mitochondrial membrane 
potential, we found modest yet significant decreases in mitochondrial membrane potential 
in populations of cells treated with 1µM sunitinib after 4hr and 8hr of treatment. 
Interestingly these time points corresponded with observed activation of caspases 3 and 7. 
We related our findings of mitochondrial dysfunction with decreases (~30%) in cellular 
ATP levels.  A limitation of these studies was that they had to be performed in 2D flat 
culture because technical factors precluded performing these experiments with cardiac 
microtissues. Nevertheless, these experiments suggest that mitochondrial dysfunction 
occur with sunitinib treatment.  
The latter part of Chapter 5 focused on addressing the hypothesis that increased 
afterload potentiates the cardiotoxic effects of sunitinib. We were able to create tissues 
under varying degrees of afterload by altering the mechanical properties of the pillars on 
which they form. Using caspase 3/7 activation as a primary metric for cardiotoxicity, we 
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found that tissues grown on stiffer pillars exhibit a higher fold change in caspase 3/7 
activation in response to sunitinib treatment compared to tissues grown on soft pillars 
(2.91±0.21 stiff vs. 1.74±0.06 soft fold increase relative to vehicle; p<0.01). These results 
demonstrate that afterload is a direct modulator of sunitinib induced apoptosis. Our results 
suggest that management of hypertension may be important for preventing eventual LV 
dysfunction in patients receiving sunitinib.  
 
7.1.3 Evaluating the effects of sunitinib in CMTs composed of human cardiomyocytes 
In the final part of this dissertation, Chapter 6, we examined the responses of 
human CMTs to sunitinib using caspase 3/7 activation as our primary metric for 
cardiotoxicity. We compared sensitivity of human and neonatal rat CMTs. We found that 
human CMTs demonstrated increased caspase 3/7 activation in response to a 
physiological dose sunitinib (1µM) similar to what we observed in neonatal rat CMTs. 
This similarity suggests that the rat CMT model can capture some aspects of sunitinib 
induced cardiotoxicity, such as changes in cell viability. Finally, we assessed how caspase 
activation in response to sunitinib is impacted by afterload in human CMTs. Similar to rat 
CMTs increased afterload augments sunitinib induced caspase 3/7 activation. However, in 
contrast to rat CMTs, human CMTs cultured on soft pillars exhibited minimal caspase 
activation in response to sunitinib. Our finding that increased afterload potentiates 
sunitinib cardiotoxicity in both rat and human CMTs strongly supports our hypothesis 
that increased afterload enhances sunitinib cardiotoxicity rather than simply unmasking in 
vivo LV dysfunction.   
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7.2 Clinical Implications of this Work 
 A key finding in this study was that afterload does not merely coincide with LV 
dysfunction in patients but actually exacerbates sunitinib-induced cardiotoxicity. 
Furthermore, our results with human CMTs demonstrate that a certain amount of 
afterload is actually required to observe sunitinib induced apoptosis, and suggests that 
management of hypertension may be important for preventing eventual LV dysfunction. 
These human studies serve as the “in vitro analog” to findings in patients that 
hypertension typically precedes or coincides with the development of LV dysfunction, 
and increases the clinical relevance of this work. We believe that our findings with 
afterload also demonstrate the need to develop more in vitro models, similar to our 
cardiac microtissue model, that can manipulate mechanical forces, as our research 
demonstrates that these forces play a role in chemotherapy induced cardiotoxicity. 
Though our findings are not sufficient to change clinical guidelines for 
managing/preventing hypertension and LV dysfunction in patients being treated with 
sunitinib, we hope this work will inspire a clinical investigations specifically examining 
whether intensive anti-hypertensive treatment can reduced the frequency and/or severity 
of LV dysfunction in patients treated with sunitinib and perhaps other tyrosine kinase 
inhibitors as well.  
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7.3 Future Work 
Most of our future work for the project will focus on further elucidating the role of 
afterload in the context of sunitinib cardiotoxicity. Future experiments will utilize human 
cardiac microtissues. We would like to expand our metrics for evaluating the effects of 
sunitinib under varying degrees of afterload. Specifically we would like to include 
experiments that measure force under varying degrees of afterload, in the presence or 
absence of sunitinib. This will require us to be able to make force measurements at a fixed 
tissue length, to account for any resting sarcomere length changes that may be occurring. 
We are actively working to develop methods to control tissue length by inserting iron 
particles in pillar caps and controlling pillar displacement with a magnet (Fig 7.1 panel 
A). Additionally, we would like to be able to induce secondary increases in afterload in 
our CMT model. We believe that this attribute would make our work more clinically 
relevant as a secondary change in afterload is a better mimic of the secondary 
development of hypertension in patients. Furthermore, if secondary increases in afterload 
can be reversed, it would give us the opportunity to begin answering the question whether 
sunitinib induced cardiotoxicity could be reversed by decreasing the amount of afterload 
on the heart. To accomplish this, we plan on using magnetic particles, except in this case 
the particles would be embedded in a very soft layer of PDMS at the bottom of the well. 
The application of a magnetic field would cause the iron particle to align, resulting in the 
hardening of the bottom layer, effectively shortening the pillars, thus increasing their 
spring constants (Fig 7.1 panel B). 
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Figure 7.1: Modifying the cardiac microtissue platform to study the effect of 
afterload on cardiac function in the context of sunitinib. A) Making force 
measurements at fixed tissue lengths by controlling pillar displacement with embedded 
iron particles and magnetics. One pillar will be pulled with a magnet to control tissue 
length by being, while the other pillar will report resulting forces. B) Secondary changes 
in afterload are accomplished by embedding iron particles into a soft layer of PDMS on 
the bottom of the wells. Under a magnetic field this bottom layer will harden 
significantly, effectively shortening pillar length, thus increasing spring constant. Figure 
credit: Elise A. Corbin, PhD. 
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Another area for future work would be to study sunitinib in human CMTs created 
from iPS lines from patients with different histories of cardiotoxicity from sunitinib. 
Penn’s Cardiovascular Institute has access to blood samples from patients undergoing 
chemotherapy, which could be used to generate iPSC lines (See section 2.3.2.2 for a 
discussion on patient specific iPS-CMs). Specifically, we would like to test weather 
iPSC-CM CMTs from patients who have experienced sunitinib cardiotoxicity have 
greater in vitro susceptibility than iPSC-CM CMTs from patients without cardiotoxicity 
despite higher exposures. If we are successful in those studies, than we would examine 
whether gene editing can mitigate sunitinib cardiotoxicity (see section 2.3.2.2 for a 
discussion on gene editing).  
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